

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing (day/month/year)</b> 02 June 2000 (02.06.00)	
<b>International application No.</b> PCT/US99/25692	<b>Applicant's or agent's file reference</b> 6627-PC9025
<b>International filing date (day/month/year)</b> 02 November 1999 (02.11.99)	<b>Priority date (day/month/year)</b> 02 November 1998 (02.11.98)
<b>Applicant</b> CHIEN, Kenneth et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

03 April 2000 (03.04.00)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	<b>Authorized officer</b> Maria Kirchner Telephone No.: (41-22) 338.83.38
--	---

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

(PCT Rule 44.1)

To:

McCLAIN, James, W.  
Attn. MUSICK, ELEANOR M.  
Brown, Martin, Haller & McClain  
1660 Union Street  
San Diego, CA 92101-2926  
UNITED STATES OF AMERICA

*Response due: Aug. 20, 2000*

Date of mailing  
(day/month/year)

20/06/2000

Applicant's or agent's file reference

6627-PC9025

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/US 99/25692

International filing date

(day/month/year)

02/11/1999

Applicant

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA et al.

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Nina Vercio

## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

#### What documents must/may accompany the amendments?

##### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.



## NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### "Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

### Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

# PATENT COOPERATION TREA

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>6627-PC9025</b>	<b>FOR FURTHER ACTION</b> <small>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</small>	
International application No. <b>PCT/US 99/ 25692</b>	International filing date (day/month/year) <b>02/11/1999</b>	(Earliest) Priority Date (day/month/year) <b>02/11/1998</b>
Applicant  <b>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.  
☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

**4. With regard to the title,**

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established by this Authority to read as follows:

**5. With regard to the abstract,**

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

**6. The figure of the drawings to be published with the abstract is Figure No.**

- ☐ as suggested by the applicant.
- ☐ because the applicant failed to suggest a figure.
- ☐ because this figure better characterizes the invention.
- ☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/25692

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-5, 12-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

MUSICK, ELEANOR M.  
McCLAIN, James, W.  
Brown, Martin, Haller & McClain  
1660 Union Street  
San Diego, CA 92101-2926  
ETATS-UNIS D'AMERIQUE

## PCT

### NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Rule 71.1)

Date of mailing (day/month/year)	26.01.2001
-------------------------------------	------------

Applicant's or agent's file reference 6627-PC9025	<b>IMPORTANT NOTIFICATION</b>
--	-------------------------------

International application No. PCT/US99/25692	International filing date (day/month/year) 02/11/1999	Priority date (day/month/year) 02/11/1998
---	--	--

Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA et al.
---

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/	Authorized officer
---------------------------------------	--------------------

 European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Hundt, D  Tel. +49 89 2399-8042
---	---------------------------------------



## PATENT COOPERATION TREATY

PCT


REC'D 30 JAN 2001

WIPO

PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 6627-PC9025	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/25692	International filing date (day/month/year) 02/11/1999	Priority date (day/month/year) 02/11/1998
International Patent Classification (IPC) or national classification and IPC A61K38/17		
Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA et al.		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 7 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"><li>I <input checked="" type="checkbox"/> Basis of the report</li><li>II <input type="checkbox"/> Priority</li><li>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li><li>IV <input type="checkbox"/> Lack of unity of invention</li><li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li><li>VI <input type="checkbox"/> Certain documents cited</li><li>VII <input checked="" type="checkbox"/> Certain defects in the international application</li><li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li></ul>		
Date of submission of the demand  03/04/2000	Date of completion of this report  26.01.2001	
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Didelon, F  Telephone No. +49 89 2399 7332	



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/25692

## I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

### Description, pages:

1-32 as originally filed

### Claims, No.:

1-17 as originally filed

### Drawings, sheets:

1/10-10/10 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/25692

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 1-5, 12-17 (with respect to industrial applicability).

because:

- ☒ the said international application, or the said claims Nos. 1-5, 12-17 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N) Yes: Claims 1-17

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/25692

---

	No:	Claims	
Inventive step (IS)	Yes:	Claims	6-11
	No:	Claims	1-5, 12-17
Industrial applicability (IA)	Yes:	Claims	6-11
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US99/25692

**Comments on item III:**

Claims 1-5 and 12-17 relate to methods of treatment of the human/animal body, which is subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**Comments on item V:**

1. Reference is made to the following documents :

D1: DILLMANN W H: 'Influences of increased expression of the Ca<sup>2+</sup> ATPase of the sarcoplasmic reticulum by a transgenic approach on cardiac contractility.' ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1998 SEP 16) 853 43-8. , XP000914521

D2: HE HUAPING ET AL: 'Influence of an antisense phospholamban transcribed by an adenoviral vector on Ca-2+ ATPase in cardiac myocytes.' JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 29, no. 6, 1997, page A181 XP000907558 ISSN: 0022-2828

D3: KOSS K L ET AL: 'PHOSPHOLAMBAN: A PROMINENT REGULATOR OF MYOCARDIAL CONTRACTILITY' CIRCULATION RESEARCH, vol. 79, no. 6, 1 December 1996 (1996-12-01), pages 1059-1063, XP002053754 ISSN: 0009-7330

D4: WO 97 37224 A (MEDICAL RES COUNCIL ;BARFORD DAVID (GB); COHEN PHILIP (GB); COHEN) 9 October 1997 (1997-10-09)

D5: FR-A-2 753 722 (SMITHKLINE BEECHAM LAB) 27 March 1998 (1998-03- 27)

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US99/25692

2. The subject-matter of the present application is considered as novel, since the available prior art does not show in vivo evidences that phospholamban deficiency improves contractile function of the cardiac muscle.
3. The present application does not meet the requirements of Article 33(3) PCT because the subject-matter of claims 1-5, 12-17 does not involve an inventive step.
  - 3.1 Document D1 shows the role of adenoviral phospholamban mutants (i.e, altered phospholamban) in increasing the activity of SERCA2 (see page 46, line 47- page 47, line 11). This study also contemplates gene therapy based on the alteration of the interaction of phospholamban-SERCA2 interaction, in particular for improving contractile function of failing heart (see page 47, line 12-18). Thus, claims 1-5 and 12-17 lack an inventive step.
  - 3.2 Similarly, document D2 discloses antisense phospholamban in an adenoviral vector in the increase of  $\text{Ca}^{2+}$  uptake and as a possible therapy to heart failure. In view of these teachings, claims 1-3 and 12-15 lack an inventive step.
  - 3.3 Document D3 reviews the role of phospholamban in the regulation of cardiac activity and suggests that the action on phospholamban would represent a strategy for the treatment of heart failure (see summary). This appears therefore to be prejudicial for the inventiveness of claims 1 and 12-13.
  - 3.4 Document D4 deals with the protein phosphatase 1 which might be modulated to enhance the phosphorylation of phospholamban, resulting in increased heart contractility, and which could represent a treatment of heart failure (see page 32, lines 1-7). Claims 1, 12 and 13 are not considered to involve an inventive step in view of this disclosure.
  - 3.5 Document D5 discloses modulators of the activity of phospholamban useful in the cardiac pathologies such as heart failure (see page 2, lines 25-31). Claims 1, 12 and 13 therefore lack an inventive step.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US99/25692

4. For the assessment of the present claims 1-5, 12-17 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**Comments on item VII:**

1. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1-D5 is not mentioned in the description, nor are these documents identified therein.

**Comments on item VIII:**

1. The subject-matter of claim 2 and 14 is directed to exogenous phospholamban protein, whereas the following dependent claims 3 and 15 comprises the use of antisense mRNA, which are two different subject-matter, resulting in a discrepancy between these dependent claims.


## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 38/00</b>		A2	(11) International Publication Number: <b>WO 00/25804</b>
			(43) International Publication Date: 11 May 2000 (11.05.00)
(21) International Application Number: PCT/US99/25692			
(22) International Filing Date: 2 November 1999 (02.11.99)			
(30) Priority Data:			
60/106,718	2 November 1998 (02.11.98)	US	
60/145,883	27 July 1999 (27.07.99)	US	
(71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 9500 Gilman Drive, Mail Code 0910, La Jolla, CA 93093-0910 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): CHIEN, Kenneth [US/US]; 9500 Gilman Drive, Mail Code 0613-C, Basic Science Building 5020, La Jolla, CA 92093-0613-C (US). DILLMAN, Wolfgang [US/US]; 9500 Gilman Drive, Mail Code 0613-C, La Jolla, CA 92093-0613-C (US). MINAMISAWA, Susanne [US/US]; 9500 Gilman Drive, Mail Code 0613-C, Basic Science Building 5027, La Jolla, CA 92093-0613-C (US). HE, Huaping [US/US]; 9500 Gilman Drive, Mail Code 0613-C, La Jolla, CA 92093-0613-C (US). HOSHIIJIMA, Masahiko [US/US]; 9500 Gilman Drive, Mail Code 0613-C, Basic Science Building 5027, La Jolla, CA 92093-0613-C (US). MEYER,			
		Markus [US/US]; 9500 Gilman Drive, Mail Code 0613-C, La Jolla, CA 92093-0613-C (US). SCOTT, Christopher [US/US]; 9500 Gilman Drive, Mail Code 0613-C, Basic Science Building 5033, La Jolla, CA 92093-0613-C (US). WANG, Yibin [US/US]; 9500 Gilman Drive, Mail Code 0613-C, La Jolla, CA 92093-0613-C (US). SILVERMAN, Gregg, J. [US/US]; 9500 Gilman Drive, Mail Code 0613-C, La Jolla, CA 92093-0613-C (US).	
		(74) Agents: MUSICK, Eleanor, M. et al.; Brown, Martin, Haller & McClain, 1660 Union Street, San Diego, CA 92101-2926 (US).	
		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published Without international search report and to be republished upon receipt of that report.	

(54) Title: A METHOD FOR INHIBITION OF PHOSPHOLAMBAN ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE AND HEART FAILURE

## (57) Abstract

The present invention provides a method for the treatment of heart failure through the use of small peptide complexes and recombinant proteins which function to enhance contractility in failing hearts and reduce blood pressure in individuals with hypertension by inhibiting the interaction between phospholamban and sarcoplasmic reticulum  $\text{Ca}^{2+}$  ATPase (SERCA2a) within cardiomyocytes. In addition, a means is provided for the transport of such therapeutic agents into the cytoplasm and nucleus of cardiomyocytes.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

## **A METHOD FOR INHIBITION OF PHOSPHOLAMBAN ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE AND HEART FAILURE**

This application claims the benefit of priority of United States  
5 Provisional Application Serial No. 60/106,718, filed November 2, 1998  
and United States Provisional Application Serial No. 60/145,883, filed  
July 27, 1999, both of which are incorporated herein by reference in their  
entirety.

### **BACKGROUND OF THE INVENTION**

#### **FIELD OF THE INVENTION**

This invention relates generally to a method for the treatment of  
heart failure, and more specifically to the inhibition of phospholamban  
(PLB) activity for the treatment of myocardial dysfunction.

15

#### **BACKGROUND INFORMATION**

Heart failure is the leading cause of combined morbidity and  
mortality in the United States and other developed countries. Congestive  
heart failure is characterized by a reduced contraction and delayed  
20 relaxation of the heart however, fundamental molecular mechanisms  
which drive the patho-physiological pathways for congestive heart are  
largely unknown. Current therapy for the heart disease is primarily  
palliative and is not targeted to the underlying biological pathways which  
are thought to lead to the initiation and progression of cardiac muscle  
25 dysfunction.

Heart muscle failure is a complex, integrative, multi-factorial disease  
in which the genetic pathways that confer susceptibility are interwoven  
with the environmental stimulus of biomechanical stress that accompanies  
heart injury, pressure and volume overload, and genetic defects in  
30 components of the cytoskeleton. In response to this biomechanical

-2-

stress, a series of parallel and converging signaling pathways are activated that lead to the adaptive response of compensatory hypertrophy.

Subsequently, there can be a transition to chamber dilation and pump failure that is associated with a loss of viable myocytes, a decrease in contractile elements, myofilament disarray and interstitial fibrosis.

Recently, the activation of signal transduction pathways which trigger the onset of programmed cell death have been implicated in promoting the pathological transition to heart failure, as well as a gp130 dependent myocyte survival pathway that can block the actions of the pro-apoptotic pathways and prevent the early onset of heart failure and cardiomyopathy. In addition to these extrinsic stress-related pathways for myocyte adaptation, there also must be intrinsic signaling pathways that lead to the impairment of cardiac excitation-contraction (EC) coupling and associated severe defects in cardiac contractile performance that are the clinical hallmarks of the progression of the heart failure phenotype.

The sarcoplasmic reticulum (SR) plays an integral role in the coordination of the movement of cytosolic  $\text{Ca}^{2+}$  throughout the cardiac tissue. In separate studies by Mercadier, *et al.* (*J. Clin. Invest.*, 1990; 85:305-309), Arai, *et al.* (*Circ. Res.*, 1993; 72:463-469), de la Bastie, *et al.* (*Circ. Res.*, 1990; 66:554-564), and Feldman, *et al.* (*Circ. Res.*, 1993; 73:184-192), research on human failing hearts and animal models of heart failure have suggested that the reduced uptake the cytosolic  $\text{Ca}^{2+}$  by the SR is responsible for prolonged diastolic relaxation.  $\text{Ca}^{2+}$  stored in the SR is released into the cytosol to activate the contraction of cardiac muscle and subsequently re-accumulated to achieve relaxation. Activity of the cardiac SR  $\text{Ca}^{2+}$  ATPase (SERCA2a) is the rate determining factor of  $\text{Ca}^{2+}$  re-uptake into the SR, and SERCA2a activity is itself regulated by phospholamban, a 52-amino acid muscle-specific SR phosphoprotein.

Phospholamban (PLB) was first identified as a major phosphorylation target in the SR membrane in research by Tada, *et al.* (*J.*

-3-

*Bio. J Chem.*, 1974; 249:6174-6180) and appeared to be a potent inhibitor of SERCA2a activity in its unphosphorylated form. The inhibitory effect of PLB on SERCA2a is reduced by an increase in intracellular calcium or by the phosphorylation of PLB in response to  $\beta$ -adrenergic stimulation. PLB exists primarily in a pentameric form, that when subjected to high temperature, dissociates into five equivalent monomers.

The amino acids of monomeric PLB are grouped into three physical and functional domains. Domains Ia and II are rich in  $\alpha$ -helices and are connected by the less structured domain Ib. Domain Ia is composed of amino acids 1-20, the majority of which are in an  $\alpha$ -helical confirmation, having a net positive charge. Domain Ib consists of amino acid residues 21-30 and constitutes the cytoplasmic sector of the monomer. Domain II amino acids 31-52, represents the transmembrane sector and is made up solely of uncharged residues that are responsible for stabilizing the pentamer formation.

PLB is a mediator in the regulation of myocardial function by catecholamines through the cAMP cascade. Ser (16) and Thr (17), in domain Ia are the confirmed binding sites for cAMP-dependent protein kinase (PKA) and Ca/calmodulin-dependent protein kinase, respectively, which function to catalyze phosphoester phosphorylation of PLB which in turn relieves its inhibition on SERCA2a activity. Because Ser (16) and Thr (17) can be phosphorylated by the kinases, the net charge of the amino acids can be shifted from positive to neutral and even to negative.

Together with the charged residues of SERCA2a, the shifting of charges in domain Ia of PLB can result in profound alterations in the protein-protein interaction of the PLB-SERCA2a system. Domain II also contains some key amino acids for functional expression of PLB, in that amino acids of one face of the domain II helix are associated with the transmembrane domain of SERCA2a.

There may be two ways in which PLB regulates  $\text{Ca}^{2+}$ -ATPase



-4-

activity: 1) a quick-acting, short-term mechanism involving PLB phosphorylation and depression of calcium pumping activity, and 2) a slower acting but longer term process involving a change in the molecular ratio of PLB to the  $\text{Ca}^{2+}$ -ATPase brought about by control of gene expression. Under physiological conditions, phosphorylation at Ser (16) by PKA is the predominant event that leads to proportional increases in the rate of  $\text{Ca}^{2+}$  uptake to the SR and accelerates ventricular relaxation. An increase in the relative ratio of PLB to SERCA2a is an important determinant of SR dysfunction in both experimental and human heart failure. Moreover, attenuated PLB phosphorylation by PKA may be responsible for impaired diastolic function and prolonged  $\text{Ca}^{2+}$  transients in failing hearts by which the  $\beta$ -adrenergic receptor-cAMP system is severely down-regulated by enhanced sympathetic tone.

A detailed mutagenesis study by Toyofuku, *et al.* (*J. Biol. Chem.*, 1994; 269:3088-3094) revealed that several amino acids in the cytoplasmic domain of PLB are important for its inhibitory function. The study showed that when the certain amino acids were mutated into amino acids of different charge, the PLB mutants lost their inhibitory effect on the co-transfected SERCA2 in HEK293 cells. However, it is still unclear whether PLB bearing these mutants can exert dominant negative effects on endogenous wild-type PLB and consequently stimulate endogenous SERCA2a in cardiac myocytes. Additionally, it is unclear how the mechanisms of transfer of these PLB point mutations into cardiomyocytes breach the cytoplasmic membrane barrier in order to effect endogenous SERCA2a activity.

Genetically based mouse models of dilated cardiomyopathy by Arber, *et al.* (*Cell*, 88:393-403; 1997) provide evidence that chamber dilation and the progression to heart failure is dependent on a specific  $\text{Ca}^{2+}$  cycling defect in the cardiac sarcoplasmic reticulum. In the mouse models, ablation of phospholamban (PLB) rescued the spectrum of

-5-

structural, functional, and molecular phenotypes that resemble heart failure. Furthermore, release of the phospholamban-SERCA2a interaction through the forced *in vivo* overexpression of a PLB point mutation dominantly activated the contractility of ventricular muscle cells. Thus, there is the possibility that interfering with the PLB-SERCA2a interaction may provide a novel therapeutic approach for preventing heart failure.

There is the understanding that interfering with the PLB-SERCA2a interaction may be a potential therapeutic target for the treatment of heart failure, however, the internalization of exogenous molecules to enhance cardiac contractility by live myocytes remains an unsolved issue. A means must be available to deliver any therapeutic agent directly to the cytoplasm and nucleus of cardiac myocytes. Penetratins, a class of peptides with translocating properties, have the ability to carry hydrophilic compounds across the plasma membrane. Research by Schwarze, *et al.* (*Science* 285:1569-1572; 1999) has demonstrated an approach to protein transduction using a penetratin-based fusion protein which contains an NH<sub>2</sub>-terminal 11- amino acid protein transduction domain from the denatured HIV TAT protein (Genebank Accession No. AF033819) . Using this non-cell-type specific transfer system allows direct targeting of oligopeptides and oligonucleotides to the cytoplasm and nucleus. One of the most well characterized translocation peptides is one that corresponds to residues 43 to 58 of antennapedia, a *Drosophila* transcription factor. It is believed that the translocation peptide interacts with charged phospholipids on the outer side of the cell membrane. Destabilization of the bilayer results in the formation of inverted micelles containing the peptide that travels across the cell membrane and eventually open on the cytoplasmic side. While the use of transport peptides to move cargo molecules into cells is not novel, it has not been demonstrated that transport peptides work well in cardiomyocytes.

Thus the need remains for methods for the inhibition of PLB through

-6-

the use of mutants or small molecule inhibitors of PLB in order to manipulate the PLB/SERCA2a interaction in cardiac myocytes, as well as a transport means for these mutants or small molecule inhibitors of PLB to cross sarcoplasmic reticulum membrane barriers into the cytoplasm of cardiac myocytes for the treatment of cardiac disease and heart failure. The present invention satisfies these needs and provides related advantages as well.

### **SUMMARY OF THE INVENTION**

It is an advantage of the present invention to provide methods for treatment of heart failure by inhibiting the effect of phospholamban on  $\text{Ca}^{2+}$  uptake in cardiac tissue.

It is another advantage of the present invention to provide both small peptide complexes and recombinant proteins which function to enhance contractility in failing hearts and reduce blood pressure in individuals with hypertension by inhibiting the interaction between phospholamban and sarcoplasmic reticulum  $\text{Ca}^{2+}$  ATPase (SERCA2a) within cardiomyocytes.

It is yet another advantage of the present invention to provide for a family of compounds that consist of a transport peptide covalently attached to wild-type, mutant, or truncated PLB.

In a first exemplary embodiment of the present invention, recombinant adenoviruses are engineered which force the expression of wild-type or mutant forms of PLB which have the ability to selectively interrupt the normal inhibitory interaction between PLB and SERCA2a and in turn dominantly activate cardiac contractility.

In a second exemplary embodiment of the present invention, contractilin, a recombinant adenoviral mutant of PLB (K3E/R14E), binds to and imitates phosphorylation of phospholamban. This leads to an activation of the calcium pump of the sarcoplasmic reticulum thus

increasing cardiac contractility.

In a third exemplary embodiment of the present invention, a compound consisting of a fusion of 1) a 16-residue transport peptide and 2) a truncated phospholamban protein or similar peptide are transported across the cell membranes in a receptor independent manner. Once inside the cytoplasm of the cardiomyocyte, the truncated phospholamban or similar peptide act as a competitive inhibitor of endogenous phospholamban interactions with SERCA2a.

#### **BRIEF DESCRIPTION OF DRAWINGS**

Figure 1 is an illustration diagramming a working model for the role of the PLB-SERCA2a interaction in the progression of heart failure.

Figure 2 shows the hemodynamic analysis of rescue of in vivo cardiac dysfunction in DKO mice (a-d) and hemodynamic assessment of  $\beta$ -adrenergic response to progressive infusion of dobutamine (e-h), where Figure 2a shows the plot for maximal first derivative of LV pressure, LV dP/dtmax. Figure 2b shows the plot for minimal first derivative of LV pressure, LV dP/dtmin. Figure 2c shows the plot for Lv end diastolic pressure. Figure 2d shows the plot for Tau. Figure 2e shows a graph of maximal first derivative of LV pressure, LV dP/dtmax. Figure 2f shows a graph of minimal first derivative of LV pressure, LV dP/dtmin. Figure 2g shows a graph of Lv end diastolic pressure. Figure 2h shows a graph of heart rate.

Figure 3 shows plotted data from the analysis of rescue of physiological calcium signaling defects in DKO myocytes, where Figure 3a is a series of graphs of representative intracellular  $\text{Ca}^{2+}$  transient in WT, MLPKO and DKO myocytes. Figure 3b is a bar graph of the amplitude of  $\text{Ca}^{2+}$  transients. Figure 3c is a bar graph of intracellular diastolic  $\text{Ca}^{2+}$  concentration. Figure 3d is a bar graph of SR  $\text{Ca}^{2+}$  content. Figure 3e is the immunoblot of MLP deficiency.

-8-

Figure 4a shows a dot blot analysis of rescue of embryonic gene markers of the heart failure phenotype in DKO mice. Figure 4b is a bar graph comparing the relative induction of mRNA for wild-type, MLPKO, and DKO myocytes.

5        Figure 5 illustrates the inhibition of the interaction between PLB and SERCA2a, where Figure 5a is a series of graphs which plot the length change in myocytes. Figure 5b is a summary of the data of cell length changes.

10        Figures 6a is a Western blot analysis of myocytes containing the adenovirus transgenes expressing sense PLB (sPLB), antisense PLB (asPLB), E2A, R14E, S16N, and K3E/R14E against monoclonal PLB. Figure 6b is a Western blot showing the results of cell infectivity by PLB, sPLB and K3E/R14E. Figure 6c illustrates the Western blot analysis of PLB infectivity of Sol8 cells.

15        Figure 7 shows a plot of SR Ca<sup>2+</sup> uptake in homogenates of neonatal rat cardiomyocytes infected with adenovirus expressing the indicated genes.

Figure 8 shows a plot of the data derived from indo 1 fluorescence-facilitated Ca<sup>2+</sup> transients of myocytes.

20

#### **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

To directly assess the role Ca<sup>2+</sup> cycling defects play in the transition to heart failure, cardiomyopathy in muscle-specific LIM protein (MLP)-deficient mice can be reversed by removing the gene that codes for PLB. Mice which harbor an ablation of MLP show many of the phenotypic features of human dilated cardiomyopathy at the molecular, cellular, and physiological levels. A uniform feature of end-stage dilated cardiomyopathy is a marked increase in cardiac wall stress that is accompanied by thinning of the chamber wall and an accompanying decrease in cardiac contractility and relaxation. Because calcium cycling is critical for both

25

30

cardiac relaxation and contractility, defects in the pathway that control calcium uptake and release from the sarcoplasmic reticulum are prime candidates for driving the progression of heart failure.

5 The creation of mice which harbor a deficiency in PLB, in addition to MLP, exhibit rescue from all the phenotypic characteristics of human heart failure normally found in MLP single knock-out (MLPKO) mice. To determine whether the functional benefits associated with PLB ablation in MLPKO mice specifically reflect the loss of the direct interaction between PLB and SERCA2a, the applicant of the present invention has engineered  
10 point mutations in the PLB gene which interrupt the functional inhibitory interaction between PLB and SERCA2a. Through the creation of recombinant adenoviruses encoding point mutations in PLB, it is demonstrated that progressive defects in excitation-contraction coupling in heart failure are related to the enhanced inhibition of SERCA2a by PLB  
15 and that the introduction of phospholamban deficiency into the setting of a transgenic model of cardiac hypertrophy results in rescued cardiac function. These results are independently supported by the fact that MLP-deficient mice harboring a transgene which directs cardiac specific overexpression of SERCA2a also exhibit rescue of the cardiomyopathy  
20 phenotype. Taken together, these results provide clear evidence that sarcoplasmic reticulum calcium cycling is critical to the progression of heart failure and points to the critical regulatory role of PLB inhibition of SERCA2a activity in the progression of heart failure. This, in turn, pinpoints the possibility of PLB as a key therapeutic target.

25 Further study of the MLP-PLB knock-out (DKO) mice indicated that the induction of PLB deficiency in the setting of cardiomyopathic mutation can result in maximal stimulation of cardiac contractile performance. The contractility of the DKO hearts at baseline levels was comparable to the contractility of wild-type hearts following maximal  $\beta$ -adrenergic  
30 stimulation. This result suggests that following the removal of the tonic

-10-

inhibition of SR calcium pump function by PLB, there is essentially a "supra-rescue" in terms of cardiac contractile function of the cardiomyopathic heart. Since PLB is a direct substrate for phosphorylation by both cyclic AMP-dependent protein kinase A and calcium/calmodulin dependent kinase, the regulation of cardiac contractility by cAMP-dependent stimuli may occur via the phosphorylation of PLB, which in turn prevents the inhibitory interaction with SERCA2a.

According to the theory behind the phosphorylation of PLB, the "supra-rescue" of the cardiomyopathic MLP-deficient mice to super-normal levels in the setting of PLB-deficiency might simply reflect the removal of the rate limiting step in the tonic inhibition of cardiac contractility. Consistent with this rationale, studies by Rockman, *et al.* (*Proc. Natl. Acad. Sci. USA* 95:7000-7005; 1998) have documented that relief of  $\beta$ -adrenergic desensitization in the MLP-deficient mice can also lead to significant rescue of the dilated cardiomyopathic phenotype. Since PLB is an SR protein that interacts with at least three regulatory components (cAMP-dependent protein kinase, calcium/calmodulin-dependent kinase, and protein phosphatase), it should be determined whether the dominant effect of PLB ablation on improving cardiac contractile performance reflects the chronic interaction of PLB with the SERCA2a or whether this rescue effect is related to the interaction of PLB with other known or novel cardiac proteins.

Utilizing recombinant adenoviruses which force the expression of wild-type and mutant forms of PLB, the present invention provides for point mutations in PLB that can selectively interrupt the normal inhibitory interaction between PLB and SERCA2a and can dominantly activate cardiac contractility in cardiac ventricular muscle cells in the absence of catecholamine. Figure 1 outlines the mechanism responsible for the rescue effect observed in the DKO mice. Both PLB and MLP are muscle-specific proteins, and as such, there must be a muscle cell autonomous

- 11 -

pathway that is required for the progression and the rescue of the phenotype, as opposed to extrinsic stress signals that promote or suppress myocyte survival pathways. Since PLB and MLP do not directly interact at the protein level, eliminating direct interaction between PLB and MLP as the basis for rescue, there must be a physiological as opposed to biochemical regulatory pathway that links the PLB regulatory pathways with the onset of dilated cardiomyopathy. As shown in Figure 1, in the normal heart, SR-calcium stores are maintained through the activity of the SERCA2a which leads to an uptake of calcium into the SR and consequent maintenance of normal cardiac relaxation and reduction in wall stress. Subsequently, SR release of calcium, via the calcium release channel, results in normal quantal calcium release and the consequent activation of the cardiac myofilaments leading to myocardial contraction. Accordingly, enhanced  $\text{Ca}^{2+}$  content in the SR leads to an enhanced  $\text{Ca}^{2+}$  release with a corresponding increase in cardiac contractility.

The activity of SERCA2a is regulated by the inhibitory effects of the direct interaction of PLB with SERCA2a, which can be relieved by the cAMP-dependent phosphorylation of PLB following the delivery of  $\beta$ -adrenergic stimuli. In the setting of heart failure, there is a relative decrease in SERCA2a function due to an inhibitory effect of PLB that arises due to blunted  $\beta$ -adrenergic responsiveness. As a result, there is less phosphorylation of PLB and a constitutive inhibition of SERCA2a, via chronic interaction with PLB, leading to a relative decrease in SR calcium content versus normal levels. This decrease in calcium stores is translated into a decrease in the quantal release of calcium through the calcium release channel and a consequent decrease in the single cell calcium transients and *in vivo* cardiac contractility. In the DKO mice, the inhibitory effect of PLB is removed, as shown in Figure 1, thereby relieving the system from the downstream inhibitory effects of PLB on the SR calcium pump, resulting in maintenance of SR calcium uptake and



-12-

reduction of wall stress towards normal levels. At the same time, this increase in SR calcium content results in maintenance of normal calcium quantal release, thereby leading to maintenance of normal contractility and relaxation.

5

*Muscle-specific LIM protein knock-out and Double knock-out mice*

Tests of the present invention were conducted using a double knock-out (DKO) mouse model which harbors homozygous ablation of two independent muscle specific genes. For this strategy, PLB knock-out (PLBKO) mice are mated into the background of MLP knock-out (MLPKO) mice which harbor molecular, structural and physiological features of the complex *in vivo* heart failure phenotype of dilated cardiomyopathy. The F3 generation of these mice are used for the actual experimentation to eliminate any potential background effects from either the PLBKO or MLPKO line on the observed cardiac phenotype of the DKO line.

MLPKO mice display a marked increase in heart/body weight ratio ( $6.34 \pm 0.22$  mg/g,  $n=8$ ) versus age and gender matched wild-type mice ( $4.60 \pm 0.21$  mg/g,  $n=7$ ;  $p<0.001$ ). The heart/body weight ratio in DKO mice ( $5.13 \pm 0.19$  mg/g,  $n=9$ ) is significantly smaller than that of MLPKO mice ( $p<0.01$ ) and is not statistically different from wild-type. To evaluate whether the decreased heart weight in DKO mice is associated with amelioration of the disrupted cytoskeletal phenotype observed in MLPKO mice, electron microscopic analysis is made of hearts from MLPKO and DKO littermates. Ablation of PLB in the background of MLP<sup>-/-</sup> rescues the wide spectrum of ultrastructural defects originally observed in the MLP deficient hearts, including myofibrillar disarray and massive fibrosis. These data suggest that ablation of PLB prevents not only the increase in total heart mass, but also prevents the disorganization of cardiomyocyte cytoarchitecture and fibrosis in MLPKO cardiomyopathic mice.

-13-

To evaluate whether the marked decreases observed in *in vivo* global cardiac function is rescued in DKO mice, echocardiography is performed with age-matched littermates. As noted in Table 1, prevention of ventricular dilation is confirmed in DKO mice. MLPKO mice have enlarged cardiac chambers, as revealed by increased left ventricular end-diastolic dimensions (LVEDD) and end-systolic dimensions (LVESD), whereas DKO mice have LVEDD in the normal range. The percent fractional shortening (%FS) and mean velocity of circumferential fiber shortening (mean Vcf), indicators of systolic cardiac function, are improved in age-matched DKO littermates, also noted in Table 1. When compared to non-littermate wild-type mice as controls, most of the echocardiographic data in DKO mice are similar to those in wild-type mice, although %FS is slightly decreased in DKO mice. Furthermore, cardiac function of DKO mice remain in the normal range beyond 6 months of age (n = 2). Despite the reduction of chamber dilation, there appears to be some hypertrophy in DKO hearts. The ratio of LVEDD to LV posterior wall thickness is markedly decreased in DKO mice, indicating that the wall stress of DKO mice is reduced in comparison to MLPKO or wild-type mice. These results indicate that global cardiac function of DKO mice is preserved in the range comparable to the parameters of control hearts. It should be noted that mice which are heterozygous for PLB deficiency display an intermediate level of functional rescue versus the MLPKO and DKO mice, suggesting that partial ablation of PLB can lead to significant functional improvement of the heart failure phenotype in MLPKO mice.

25

-14-

Table 1

## Echocardiographic assessment

	MLPKO n = 12	MLPKO/PLBhet n = 12	DKO n = 10	wild-type n = 10
5				
LVEDD (mm)	4.87 ± 0.14	4.10 ± 0.15***	3.75 ± 0.12***	3.89 ± 0.11***
LVESD (mm)	3.94 ± 0.18	3.06 ± 0.22***†	2.60 ± 0.10***	2.44 ± 0.07***
FS(%)	19.4 ± 1.7	26.2 ± 3.2*‡	30.6 ± 1.8***†	37.2 ± 1.4***
SEpth (mm)	0.68 ± 0.05	0.86 ± 0.05*‡	0.83 ± 0.05*‡	0.64 ± 0.01
Pwth (mm)	0.67 ± 0.05	0.86 ± 0.05*‡	0.81 ± 0.04*†	0.64 ± 0.06
10				
LVEDD/ Pwth(mm/mm)	7.47 ± 0.30	5.00 ± 0.47***	4.74 ± 0.30***	6.14 ± 0.18*
mean Vcf (circ/s)	3.38 ± 0.33	4.81 ± 0.73#	6.10 ± 0.41***†	4.41 ± 0.61
mean Vcfc (circ/s)	1.41 ± 0.17	1.96 ± 0.27*	2.37 ± 0.13***	2.23 ± 0.10**
Heart Rate (beats/min)	351 ± 15	350 ± 15§	396 ± 13§	239 ± 14***
15				
Age (days)	65.3 ± 2.5	65.5 ± 4.5‡	67.4 ± 1.9‡	80.5 ± 1.2**
Body Weight (g)	26.7 ± 1.3	26.8 ± 0.9§	25.0 ± 1.3§	36.9 ± 2.2***

MLPKO vs. MLPKO/PLBhet or DKO or wild-type; \*: p&lt;0.05, \*\*: p&lt;0.01, \*\*\*: p&lt;0.001

wild-type vs. MLPKO/PLBhet or DKO; †: p&lt;0.05, ‡: p&lt;0.01, §: p&lt;0.001

MLPKO/ PLBhet vs. DKO; #: p&lt;0.05

MLPKO mice have demonstrated a marked blunting of  $\beta$ -adrenergic responsiveness and decreased adenylyl cyclase activity. Ablation of PLB by homologous recombination in mice can augment cardiac contractile performance to a level comparable to that with maximal  $\beta$ -adrenergic stimulation of the normal heart. To confirm that the ablation of PLB can reverse the hemodynamic defects and marked  $\beta$ -adrenergic receptor desensitization associated with dilated cardiomyopathy, anesthetized mice are cardiac catheterized and assessed.

Several independent hemodynamic parameters document the rescue of the severe cardiac dysfunction with circulatory congestion to normal levels in the DKO mice. LV contractility (assessed by LV dP/dtmax) and

-15-

relaxation (assessed by LV dP/dtmin) at baseline appears to be higher than that of wild-type mice and is comparable to PLBKO mice, as is shown in Figures 2a and 2b. Ablation of PLB reverses the markedly elevated LV end diastolic pressure observed in the MLPKO cardiomyopathic mice, as  
5 seen in Figure 2c.

Analysis of Figure 2d illustrates that Tau, an indicator of LV relaxation and diastolic function, are also normalized in the DKO mice, which is consistent with an improvement in wall stress. These data suggest that ablation of PLB can rescue both the systolic and diastolic  
10 dysfunction in the cardiomyopathic MLPKO mice. The blunted responses of LV dP/dtmax and LV dP/dtmin to  $\beta$ -adrenergic stimulation is observed in MLPKO mice, as shown in Figures 2e and 2f, indicating the presence of severe  $\beta$ -adrenergic desensitization in MLPKO mice. There is no stimulation of cardiac contractility (LV dP/dtmax) and relaxation (LV  
15 dP/dtmin) by dobutamine in DKO mice, as is again shown in Figures 2e and 2f. These parameters are already stimulated to their maximal levels under basal conditions in the DKO hearts.

After maximum stimulation of wild-type hearts by dobutamine, LV dP/dtmax and LV dP/dtmin are indistinguishable from these parameters in  
20 the DKO mice in the absence of any catecholamine stimulation. This evidence confirms that the interaction of PLB and SERCA2a suppresses cardiac contractility in both normal and myopathic hearts, and that inhibiting this interaction may exert a dominant effect on maximizing cardiac performance in the absence of any catecholamine stimulation.  
25 Figure 2h shows that chronotropic responsiveness to dobutamine is preserved in both DKO mice and MLPKO mice, thereby documenting the specificity of the  $\beta$ -adrenergic response to ventricular myocytes versus pacemaker cell types.

To determine the mechanisms responsible for the rescue of *in vivo* cardiac function in DKO mice, several independent parameters of  $\text{Ca}^{2+}$   
30

-16-

signaling are assessed. It is apparent that altered  $\text{Ca}^{2+}$  homeostasis in DKO mice leads to the hemodynamic changes, intracellular  $\text{Ca}^{2+}$  transients and the expression of proteins related to  $\text{Ca}^{2+}$  cycling in the SR. MLPKO myocytes exhibit an attenuated amplitude of  $\text{Ca}^{2+}$  transients with normal levels of diastolic  $\text{Ca}^{2+}$  concentration, as is shown in Figures 3a-c. The rate of decay is slightly accelerated in MLPKO mice which suggests that a compensatory mechanism is operative during the end of  $\text{Ca}^{2+}$  uptake in MLPKO mice. Ablation of PLB is associated with a shortened duration of the  $\text{Ca}^{2+}$  transient, faster decay and preserved amplitude. Figure 3d shows that SR  $\text{Ca}^{2+}$  content is significantly decreased in MLPKO mice and increased in DKO mice as compared to wild-type mice. Quantitative immunoblotting, shown in Figure 3e, reveals that MLP deficiency is not associated with any significant alterations in protein levels of SERCA2a, PLB and calsequestrin, suggesting that the defects of  $\text{Ca}^{2+}$  cycling in MLPKO mice is based upon functional impairment of EC coupling, as opposed to simply reflecting decreases in the protein levels of either SERCA2a or phospholamban.

One of the characteristic features of heart failure is the reactivation of an embryonic gene program which may contribute to a compensatory response to an increased hemodynamic load. To confirm that hemodynamic improvement in DKO mice is accompanied by amelioration of changes at the transcriptional level, the expression of ANF,  $\alpha$ -skeletal actin, and  $\beta$ -MHC mRNAs, well established embryonic markers for heart failure, is examined. As shown in Figures 4a and 4b, ventricles of MLPKO mice display a 26-fold increase in ANF, a 13-fold increase in  $\alpha$ -skeletal actin and an 8-fold enhancement of  $\beta$ -MHC mRNAs. DKO mice exhibits only a 1.9-fold increase in ANF and no significant increase in  $\alpha$ -skeletal actin or  $\beta$ -MHC mRNAs. Thus, ablation of PLB largely suppresses induction of the embryonic gene program in MLPKO mice.

The aforementioned studies indicate that the ablation of PLB can

-17-

rescue independent parameters of heart failure and associated defects in cardiac contractility. To define the mechanism of the rescue effect, it is necessary to assess whether the chronic interaction of PLB and SERCA2a is in fact limiting for cardiac contractility in both normal and myopathic hearts. The "supra-rescue" of basal cardiac function in the DKO mice to levels comparable to those in wild-type mice following maximal catecholamine stimulation suggests that inhibition of this interaction may exert a dominant effect to maximize cardiac performance in the absence of any catecholamine stimulation.

#### *Recombinant Adenoviral transgene mutants of PLB*

Using the knowledge that certain amino acid residues of PLB are required to maintain its inhibitory effects on SERCA2a, several single point mutations of PLB, V49A (Seq. ID. No. 2), E2A (Seq. ID. No. 3), R14E (Seq. ID. No. 4), S16N (Seq. ID. No. 5), a double point mutation of PLB, K3E/R14E (Seq. ID. No. 6) and a sense and antisense PLB (Seq. ID. No. 1) transgene can be engineered in order to disrupt the inhibitory effects of PLB on SERCA2a. Using recombinant adenoviruses for *in vivo* murine cardiac gene transfer, myocytes which overexpresses V49A, one of the single point mutations in PLB, exhibit an increase in contractility, while myocytes which overexpress the wild-type PLB exhibit a decrease in contractility when compared to non-infected myocytes, as is documented in Figure 5. It can be concluded that the feasibility and utility of interfering with the interaction between the SERCA2a and PLB is clearly documented. The PLB-SERCA2a interaction appears to be the rate limiting step for establishing the set point of basal cardiac contractility and relaxation *in vivo*, and the disruption of this interaction can thereby short circuit the  $\beta$ -adrenergic pathway.

Additional Western blot analysis of myocytes containing the adenovirus transgenes expressing sense PLB (sPLB), antisense PLB

-18-

(asPLB), E2A, R14E, S16N, and K3E/R14E against monoclonal PLB antibody (Affinity BioReagents) is shown in Figure 6a. Quantification of PLB protein content, normalized to  $\alpha$ -actin for loading variance and compared with an adenovirus/ SR control lacking the transgene, shows that sPLB, E2A, and R14E mutants increase PLB protein level by 150% (PLB<sub>5</sub> + PLB<sub>1</sub>), 72 %, and 57%, respectively. In contrast, asPLB and S16N results in 54% and 33% decrease in PLB protein content within the myocytes. The introduction of K3E/R14E transgene infection of myocytes leads to a formation of a distinct pattern of pentamer PLB. Multiple PLB bands appear in addition to PLB<sub>5</sub> (the pentamer). This is accompanied by a reduced abundance of PLB<sub>5</sub> in comparison with the control.

The nature of the Western blot banding pattern is further evaluated by substituting PLB-deficient Sol8 cells in place of cardiac myocytes. Sol8 cells are infected with the recombinant adenovirus expressing either the transgene sPLB or K3E/R14E alone or in combination. As seen in Figure 6b, the Western blot shows that the monoclonal PLB antibody detects PLB in cells infected by sPLB but fails to detect K3E/R14E. Infection of Sol8 cells with a combination of the adenoviral transgenes results in formation of multiple bands of PLB. Moreover, the PLB pentamer decreases in abundance simultaneously with the appearance of the upper bands. It is well established that PLB interacts with and inhibits SERCA2a predominantly as a monomer that exists in equilibrium with the noninhibitory pentamer. Based on this knowledge, the heteropentamer of K3E/R14E and wild-type PLB might be more stable than the homopentamer of wild-type PLB. Therefore, the dissociation of the heteropentamer into monomers, which results in inhibition of SERCA2a, is disfavored. K3E/R14E interacts with endogenous PLB and forms such a complex, accompanied by a decrease in homopentamer formation. In as much, the monomer K3E/R14E may act as a noninhibitory competitor for endogenous wild-type PLB by blocking SERCA2a-PLB interaction sites.

-19-

The effects of mutant and antisense PLB on SERCA2a is further evaluated by determination of the SR calcium uptake activity. The initial rate of  $\text{Ca}^{2+}$  uptake by the SR measured at varying  $\text{Ca}^{2+}$  concentrations reflects the activity of SERCA2a. As shown in Figure 7, neonatal rat myocytes infected with the recombinant adenovirus transgenes K3E/R14E and asPLB show a decrease in the concentration of  $\text{Ca}^{2+}$  needed by SERCA2a for the same activity compared with the non-transgene control, indicating a stimulation of SERCA2a activity. The  $\text{EC}_{50}$ s of  $\text{Ca}^{2+}$  concentration at which the uptake activity is half-maximal are, (in  $\mu\text{mol/L}$ ), 0.20  $\pm$  0.02 for the non-transgene control (SR-), 0.11  $\pm$  0.01 for K3E/R14E, and 0.13  $\pm$  0.01 for asPLB. The effects of K2E/R14E and asPLB on SERCA2a are also examined in adult rat myocytes. The adenoviral transgene K3E/R14E lowers the  $\text{EC}_{50}$  significantly (by 36%), whereas the change as a result of asPLB infection is not within statistical significance. This apparent discrepancy in the effects between neonatal and adult cardiac myocytes is possibly related to the different abundances of PLB in myocytes at different developmental stages. PLB is nearly twice as abundant in adult as in neonatal myocardium.

To further examine the effects of K3E/R14E and asPLB on SERCA2a, intracellular  $\text{Ca}^{2+}$  transients in neonatal myocytes are measured by use of the indo 1 fluorescence indicator. Indo 1 ratiometric data which is obtained from each of the experimental conditions is normalized to the respective maximum and minimum of each contractile  $\text{Ca}^{2+}$  transient and is then aligned and averaged. As shown in Figure 8, the decay curves of K3E/R14E and asPLB are displaced to the left of the LacZ control. Furthermore, for most of the diastolic time points, K3E/R14E is significantly different from LacZ, whereas at several diastolic time points, asPLB is also significantly different from LacZ. The half-times for decay ( $\text{RT}_{50}$ ) for LacZ, K3E/R14E, and asPLB are determined to be 0.28 seconds (100%), 0.20 seconds (73%), and 0.22 seconds (79%), respectively.



-20-

The values for K3E/R14E (73%) and asPLB (79%) are significantly different ( $p < 0.05$ ) from the values obtained from the LacZ expressing virus.

In addition to generating adenoviral transgenes using various point mutations of PLB, or the sense or antisense sequences of PLB, antibodies raised against PLB peptide and then expressed as RNA can also be inserted into the adenoviral vector. To raise polyclonal PLB antibody ("contractilin", or chicken antibody peptides with hyperactive regions), a chicken is repeatedly immunized with PLB peptide which represents amino acids 3 to 19 of the cytoplasmic domain. After three rounds of booster immunization, administered at 15, 42 and 54 days, total IgY is purified from the egg yolk, using a commercially available purification system (EGGstract IgY Purification System - Promega). Upon confirmation of a positive immune response, lymphocytes from the spleen and bone marrow are harvested. RNA, in the form of the hypervariable regions from both antibody light and heavy chain is obtained from these cells and amplified by RT-PCR, the method of which is well known.

The amplified and purified hypervariable region RNA is then fused to a single cDNA (Seq. ID. No. 9) and subsequently cloned in frame into a plasmid vector, coding for a phage surface protein. Using standard phage display technique, phages which express the immune library of the chicken are selected by their positive response to the PLB peptide. After a series of enrichment for phages which specifically bind PLB, 20 clones are selected for ELISA. The resulting 5 best binders are then analyzed using a radioactive  $\text{Ca}^{2+}$  transport assay. The two best activators of SR  $\text{Ca}^{2+}$  transport are further analyzed. Both clones are found to dramatically stimulate the rate of  $\text{Ca}^{2+}$  transport into the SR.

To demonstrate that the recombinant protein, which has been generated from contractilin (the PLB antibody), can also function inside a living cell, an adenoviral vector expressing contractilin is constructed.

-21-

Western blot analysis of neonatal and adult rat cardiomyocytes, infected with the adenoviral transgene, shows that contractilin can be expressed in heart cells. Radioactive  $\text{Ca}^{2+}$  transport analysis indicate that, as with the mutant and antisense PLB, contractilin accelerates cytoplasmic  $\text{Ca}^{2+}$  removal.

In a complementary approach, plasmid transfection rather than adenoviral transfection is used for gene delivery. It is found that K3E/R14E- and asPLB- transfected myocytes, as monitored by co-transfected green fluorescence protein, exhibits 43% ( $p < 0.05$ ) and 9% ( $p < 0.1$ ) decreases in  $\text{RT}_{50}$ , respectively, relative to adenoviral vector transfected cells. Thus, introducing K3E/R14E and asPLB into the cardiac myocytes by either the adenovirus or co-transfection technique reduces the duration of the diastolic  $\text{Ca}^{2+}$  transients. These results would seem to mirror the findings of MLPKO versus DKO mice where variation in  $\text{Ca}^{2+}$  transients confirm that ablation of PLB is associated with a shortened duration of  $\text{Ca}^{2+}$  transient, faster decay, and preserved amplitude. Taken together, these data confirm that K3E/R14E and asPLB stimulate the SERCA2a activity, which results in faster  $\text{Ca}^{2+}$  transients in myocytes.

To determine whether the enhanced SERCA2a activity and accelerated  $\text{Ca}^{2+}$  transients, as a result of the PLB mutants, lead to change in contractile behavior, edge detection is used to analyze myocyte contractility. Adult rabbit myocytes are infected with the adenoviral transgenes of LacZ, K3E/R14E, or asPLB. After a three day incubation period, there is a significant difference in the number of spontaneously contracting cells between the different groups (LacZ  $<$  asPLB  $<$  K3E/R14E). Table 2 provides the effects of K3E/R14E and asPLB on myocyte contractility. As shown in the table, compared with the LacZ control, K3E/R14E increases fractional shortening by 74%, which is accompanied by a 25% decrease in  $\text{RT}_{50}$  and a 115% increase in  $+dL/dt$ . When the myocyte contractility is examined after asPLB infection, it is

-22-

found that the fractional shortening of the myocytes increases significantly, by 57%, whereas the changes in  $RT_{50}$  and  $+dL/dt$  are not significant.

Table 2

	LacZ (n = 33)	K3E/R14E (n = 29)	asPLB (n = 30)
+ dL/dt ( $\mu\text{m/s}$ )	$11.7 \pm 1.9$	$25.1 \pm 1.6^*$	$18.4 \pm 2.0^*$
$RT_{50}$ (ms)	$539.0 \pm 27.0$	$402.0 \pm 19.0^*$	$483.0 \pm 29.0^{***}$
Shortening (%)	$6.2 \pm 0.5$	$10.8 \pm 0.5^*$	$8.0 \pm 0.6^{***}$

\*:  $p < 0.05$

\*\*:  $p < 0.1$

The resulting data show that the increase in SERCA2a activity translates into an accelerated relaxation of the myocytes. K3E/R14E-infected myocytes display an enhanced fractional shortening, which suggests an increase in SR loads of  $\text{Ca}^{2+}$  due to the enhancement of SERCA2a activity. Further, K3E/R14E infection increases the number of spontaneously contracting myocytes, a phenomenon most likely associated with the increased amount of oscillating  $\text{Ca}^{2+}$  due to the elevated SR loading of  $\text{Ca}^{2+}$ . Taken together, these data show that K3E/R14E affects endogenous wild-type PLB in a way that significantly reduces its inhibition of SERCA2a and thus has a dominant inhibitory effect over wild-type PLB.

#### *Peptide-based therapeutic for inhibition of PLB activity*

Still further, the present invention provides for a peptide based therapeutic for the inhibition of phospholamban activity and a mode of delivery for such a therapeutic, based on the finding that PLB function can be inhibited in a dominant negative manner by overwhelming endogenous PLB with mutant PLB molecules, and that this inhibition leads to improved function in failing hearts.

-23-

For a therapeutic agent, such as an inhibitor of the PLB-SERCA2a interaction, to effect a target cell system, it must have a means for internalization through the cell membrane into the cytoplasm. The mode of transfer of the inhibitor can be by way of either a transport or  
5 penetratin based PLB peptide or it can also include adenoviral or lipid vesicle based transfer. For this purpose, a compound consisting of a fusion of a transport peptide and a PLB protein molecule is constructed. The transport peptide comprises a 16-residue from the sequence for antennapedia, a Drosophila transcription factor protein. The second  
10 peptide of the complex can be a truncated sequence of PLB protein. Further therapeutic benefits can be achieved using peptides that correspond to native PLB protein as well as a mutant or truncated form of PLB protein.

One beneficial function of the transport peptide-PLB complex is the  
15 inhibition of the interaction between PLB and SERCA2a within cardiomyocytes, resulting in enhanced contractility in diseased hearts. The present invention may also inhibit the interaction of PLB with SERCA2a within the smooth muscle layer surrounding the arteries/  
arterioles of the circulatory system which would result in vasodilation and  
20 reduced blood pressure. Thus, there is a two-fold benefit in the treatment of heart disease, the first is enhanced cardiac contractility in failing hearts, the other is the reduction of blood pressure in individuals with hypertension. It is also predicted that there will be the inhibition of PLB  
interactions with SERCA proteins of other cell types, such as the  
25 SERCA1-PLB interaction in nervous tissue.

The introduction of the molecule into the blood stream feeding the heart can be best achieved using a catheter located in the coronary artery. When the molecule is present in the extracellular environment surrounding a cardiomyocyte it rapidly enters the cardiomyocyte and inhibits the  
30 association of PLB with SERCA2a. The translocation function is

-24-

attributable to the transport peptide which exhibits the ability to rapidly translocate itself and the attached "cargo" peptides across the cell membranes in a receptor independent manner. Once inside the cytoplasm of the cardiomyocyte, the PLB fragment will act as a competitive inhibitor of endogenous PLB interactions with SERCA2a.

In the absence of PLB inhibition by association, SERCA2a more efficiently pumps  $\text{Ca}^{2+}$  into the SR, thereby increasing the cardiomyocytes ability to contract more strongly and rapidly. Stronger cardiomyocyte contractility translates to more powerful heart contractility. *In vivo*, the present invention could act as a treatment for heart failure and is most easily administered and most effective in patients whose hearts require, or already have implanted, a left-ventricular assist device (LVAD).

While residues 43 to 58 of Antennapedia is a well characterized translocation peptide, and works well in the present invention, the present invention is not restricted to this method of transport. Other potential methods of transfer include the use of an 8-branched polylysine backbone to link the transport and cargo peptide, but it is not limited to this multi-branched structure. A compound consisting of one target peptide attached to one PLB peptide, as one long peptide, has also been explored. Still further, a number of DNA constructs for producing hexahistidine (H6) tagged penetratin and penetratin-PLB recombinant proteins in bacteria have been undertaken. The penetratin peptides were engineered to be on either the amino or carboxy terminal end of the protein.

It has been shown that the cytoplasmic fragment of PLB has as strong a binding affinity for the cytoplasmic portion of SERCA2a as the whole PLB molecule. Therefore, once the transport-PLB molecule is inside the cytoplasm of the cardiomyocyte, the PLB fragment is predicted to act as a competitive inhibitor of endogenous PLB interaction with SERCA2a.

This form of treatment is suitable for the patient who is suffering from severe decreased cardiac pump function, refractory to medical

-25-

therapy, and requiring mechanical assistant devices while waiting for heart transplantation. In addition, the underlined molecular mechanisms for the dominant negative function of the PLB mutants can be used in the design and implementation of the high-throughput screening strategies for inhibitory small molecules.

The following examples are intended to illustrate but not limit the present invention.

### EXAMPLE1

#### 10 Creation of knock-out mouse lines for echocardiography

In order to analyze the structural and physiological features of the complex *in vivo* heart failure phenotype of dilated cardiomyopathy, several lines of knock-out mice were created. conducted using a double knock-out (DKO) mouse model which harbors homozygous ablation of two independent muscle specific genes. For this strategy, PLB<sup>-/-</sup> (phospholamban deficient) homozygous mice were mated with MLP<sup>-/-</sup> (muscle-specific LIM protein) homozygous mice. The F1 pups generated from an MLP<sup>-/-</sup> x PLB<sup>-/-</sup> homozygote cross were then mated to create the MLP<sup>+/-</sup>, PLB<sup>+/-</sup> double heterozygote genotype. F2 offspring were generated from a MLP<sup>+/-</sup> / PLB<sup>+/-</sup> double heterozygote mating, thereby creating mice that were homozygous for the mutant MLP allele and heterozygous for the mutant PLB allele or that were MLP wild-type and heterozygous for the mutant PLB allele. The F3 offspring were generated from a MLP<sup>-/-</sup> / PLB<sup>+/-</sup> matings to generate MLP<sup>-/-</sup> / PLB<sup>-/-</sup> (DKO), MLP<sup>-/-</sup> / PLB<sup>+/+</sup> (MLPKO) and MLP<sup>+/-</sup> / PLB<sup>-/-</sup> (MLPKO/ PLBhet) littermates or from a MLP<sup>+/+</sup> / PLB<sup>+/-</sup> matings to generate MLP<sup>+/+</sup> / PLB<sup>-/-</sup> (PLBKO), MLP<sup>+/+</sup> / PLB<sup>+/+</sup> (wild-type) and MLP<sup>+/+</sup> / PLB<sup>+/-</sup> (PLBhet) littermates. The genotype of the gene-targeted crosses were determined by PCR or genomic DNA isolated from tail biopsies.

30 To evaluate the hemodynamic properties of the various knock-out

-26-

mouse lines, cardiac catheterization and echocardiography was performed on subjects anesthetized with either Avertin (2.5%, 20  $\mu$ l/kg body weight) or xylazine (0.005 mg/g) and ketamine (0.1 mg/g). Transthoracic M-mode echocardiographic tracings indicated that MLPKO mice had chamber  
5 dilation with reduced wall motion, indicating depressed cardiac function and increased wall stress, whereas chamber size and cardiac function are normal in the DKO mice. Baseline parameters for wild-type (WT), n = 7, MLPKO, n = 8, DKO, n = 9, and PLBKO, n = 5 are shown in Figures 2a-d. Data were expressed as mean  $\pm$  SEM. MLPKO versus other groups;  
10 \*p < 0.5, \*\*p < 0.001, WT vs. DKO; #p < 0.01. In Figures 2e-h, hemodynamic assessment was made of  $\beta$ -adrenergic responsiveness to progressive infusion of dobutamine, where WT ( $\square$ ), n = 7, MLPKO ( $\bullet$ ), n = 8, and DKO ( $\circ$ ), n = 9, mice. MLPKO vs WT or DKO; #p < 0.05, \*p < 0.01, \*\*p < 0.001, WT vs DKO;  $\exists$ p < 0.01.

15

## EXAMPLE 2

### Calcium transient analysis

To evaluate the effect of inhibition of PLB on SR calcium content and calcium transients, myocytes were isolated from the right ventricular  
20 wall of the wild-type or knock-out mice. To monitor the changes in intracellular calcium, the isolated myocytes were incubated with a calcium sensitive dye, fluo-3-AM (1  $\mu$ g/ml), for 30 minutes at room temperature. The myocytes were then transferred to a tissue chamber on the stage of an inverted microscope and continuously stimulated at a rate of 1 Hz to  
25 maintain a consistent degree of SR calcium loading. To measure cellular fluorescence, the myocytes were illuminated with an excitation wavelength of 480 nm. Any changes in fluorescence were monitored at 510 nm using a microfluorometer (FM-1000; Solamere Technologies) and digitally recorded for later analysis using Cellsoft (D. Bergman; University  
30 of Calgary) software. Fluorescence values were calibrated using the

-27-

equation:

$$[Ca^{2+}]_i = K_D(F-F_{min})/(F_{max}-F) \quad (1)$$

with an assumed  $K_D$  of 864 nM, where  $F$  are the experimentally derived fluorescence values.  $F_{max}$  was determined by adding 10  $\mu$ M ionomycin to the superfusion solution and  $F_{min}$  was determined by adding 4 mM  $MnCl_2$  to the superfusion solution for each myocyte.

SR calcium content of the isolated myocytes was assessed using a standard caffeine pulse protocol. Following stable recordings of calcium transients, a 20 second pulse of 10 mM caffeine was applied to the myocyte. This protocol resulted in a rapid caffeine-induced transient which slowly decayed back to baseline values. The SR calcium content was defined as the integrated area of this caffeine-induced calcium transient. Figure 3a illustrates the representative intracellular calcium transient in the WT, MLPKO and DKO myocytes. MLPKO myocytes exhibited an attenuated amplitude of calcium transients with normal levels of diastolic calcium concentration. DKO myocytes displayed the calcium transient with a shortened duration, faster decay, and preserved amplitude. As shown in Figure 3b, the amplitude of calcium transient was significantly attenuated in MLPKO myocytes and was restored in DKO myocytes. Figure 3c shows that intracellular diastolic calcium concentration was not different among the three different groups of myocytes. In Figure 3d, SR calcium content was significantly decreased in MLPKO mice and increased in DKO mice when compared to WT mice. In Figure 3e, representative quantitative immunoblotting revealed that MLP deficiency was not associated with any significant alterations in the protein levels of SERCA2a, PLB, and calsequestrin.

### EXAMPLE 3

#### Construction of mutant PLB adenovirus and gene transfer

I.M.A.G.E. consortium cDNA clones encoding human PLB were



-28-

available through Genome System, Inc. The DNA fragment harboring the entire coding sequence of PLB was subcloned into pBluescriptII KS vector, as well known *E. coli* cloning vector (ATCC accession no. 87047). A sense mutation (Val49Ala) was introduced using a PCR based

5 mutagenesis system commercially available from Stratagene.

Recombinant adenovirus expressing wild-type and mutant human PLB was generated by homologous recombination between plasmid pJM17 and a shuttle plasmid containing RSV promoter and SV40 poly A sequences.

The concentrated virus preparation were tittered using a standard  
10 protocol. The efficient *in vivo* cardiac gene transfer was performed by injecting the adenovirus vectors into 1 day old neonatal mouse heart. The myocytes were isolated 4 weeks after injection into the mouse hearts and cell shortening was measured. Myocytes harboring the mutant transgenes were identified by co-transfection of adenoviral vectors expressing GFP as  
15 a marker.

#### EXAMPLE 4

##### Construction of a PLB inhibitor-transport peptide complex

A PLB inhibitor molecule was made by indirectly attaching a  
20 transport peptide and a PLB protein to a polylysine backbone. Alternatively, the PLB molecule could also have been made as a single long peptide consisting of a transport sequence tandemly attached to the cargo peptide sequence. The transport peptide was composed of residues 43 to 58 of antennapedia (Seq. ID. No. 7), a *Drosophila* transcription  
25 factor protein. The cargo peptide was derived using the first 16 residues of PLB (Seq. ID. No. 8). It is important to note that this cargo sequence could also have been derived from any segment of wild-type PLB or mutant PLB.

The PLB inhibitor molecule was constructed by linking 4 transport  
30 peptides with 4 peptides matching the first 16 residues of PLB. The

-29-

backbone linker was an 8-branch lysine, commonly used in multiple antigenic peptide (MAP) synthesis. The first 4 branches of the MAP resin were used to synthesize the antennapedia peptide. The next 4 branches were then deprotected and used as the starting point for the synthesis of the PLB cargo peptide. Thus, this particular PLB inhibitor that was used for initial characterization had 4 branches of the antennapedia peptide and 4 branches of the PLB cargo peptide. Alternatively, the PLB inhibitor could have been constructed as a single peptide with the cargo and transport peptides attached to each other by a single peptide bond, or as the cargo and transport peptides attached to each other by a disulfide bond. The PLB inhibitor molecule was translocated efficiently into isolated neonatal rat cardiomyocytes and showed a resulting enhanced contractility of the cell, the results of which can be seen in Figures 5a and b. Myocytes that overexpressed the V49A PLB point mutation showed increased contractility, while myocytes which overexpressed the wild-type PLB exhibited decreased contractility when compared to non-infected myocytes.

## EXAMPLE 5

### Penetratin peptides TAT and ANT

Cell level studies were done to evaluate the ability of two penetratin-based peptides, two mutant PLB-penetratin peptides, and two multiple antigen peptides (MAP) to strengthen the contraction cycle of isolated mouse cardiomyocytes. The two penetratin-based peptides include PLB-ANT (Seq. ID. No. 10) and TAT-PLB (Seq. ID. No. 11) each of which have a 20 residue portion of the PLB sequence attached to either the 5' end of ANT (Seq. ID. No. 14) or the 3' end of TAT (Seq. ID. No. 15). The two mutant PLB peptides, mutant PLB-ANT (Seq. ID. No. 12) and TAT-mutant PLB (Seq. ID. No. 13), display a S16E mutation of the 20 residue PLB sequence. The multiple antigen peptides include MAP with 8 penetratin

-30-

(ANT) domains and MAP with 4 penetratin domains and 4 PLB domains .

Each of the penetratin-PLB peptides were evaluated to measure their ability to strengthen the contraction cycle of isolated mouse cardiomyocytes, the idea being that the penetratin-PLB peptide would act as a dominant negative inhibitor of the PLB-SERCA2a interaction. The results of the TAT-PLB peptide on the isolated cardiomyocytes is shown in Table 3. For this data, tests were repeated on several sets of cardiomyocytes to determine relative change in length through the contraction cycle with the TAT-PLB peptide (samples 1-7) and without the peptide (controls 1-8). Each of the samples had an added concentration of 10  $\mu$ M of the TAT-PLB peptide while the controls had no added peptide.

Table 3

		Maximum Contract.	Minimum Contract.	% Contract.	$\Delta$ Length/ msec.	r2 (fit)	Contract. Slope	Relax. Slope
15	control 1	100.63	92.978	7.604	-34.503	0.9696	29.935	0.9955
	control 2	91.146	83.301	8.607	-38.76	0.9943	28.736	0.9349
	control 3	115.45	100.05	13.339	-82.875	0.9768	89.054	0.9894
	control 4	105.00	102.04	2.819	-19.196	0.9842	10.497	0.9944
	control 5	83.747	79.637	4.908	-21.695	0.9971	12.184	0.9742
20	control 6	145.96	136.85	6.241	-50.185	0.9721	27.566	0.9912
	control 7	154.56	142.16	8.023	-76.607	0.9933	73.70	0.9928
	control 8	115.59	102.68	11.169	-59.643	0.9765	63.304	0.9789
	<b>Mean</b>	<b>114.010</b>	<b>104.962</b>	<b>7.839</b>	<b>-47.933</b>	<b>0.9830</b>	<b>41.872</b>	<b>0.9814</b>
	sample 1	112.57	101.17	10.127	-65.554	0.9865	59.875	0.9925
25	sample2	109.68	102.00	7.002	-30.267	0.9609	37.157	0.9790
	sample3	133.82	116.32	13.077	-79.242	0.9964	134.46	0.9878
	sample 4	81.61	67.871	16.835	-58.093	0.9961	65.017	0.9697
	sample 5	74.423	64.629	13.160	-54.353	0.9539	47.775	0.9933
	sample 6	126.89	108.38	14.587	-98.054	0.9819	107.07	0.9939
30	sample 7	133.61	128.21	4.042	-36.071	0.9966	27.911	0.9959
	<b>Mean</b>	<b>110.373</b>	<b>98.363</b>	<b>11.261</b>	<b>-60.233</b>	<b>0.9818</b>	<b>68.466</b>	<b>0.9874</b>

-31-

Measurements were taken every 20 milliseconds, and the unit of length was arbitrary, but was generally on the order of one complete cell length. Percent contraction was calculated as (maximum length minus minimum length) divided by maximum length. A plot of time versus length  
5 generated a U-shaped curve from which the most linear segments were selected, with the left side of the "U" representing contraction and the right side representing relaxation. The  $r^2$  column shows how well the data fit the curve, where 1.0 represents a perfect fit.

While there appeared to be a trend towards a larger, faster  
10 contraction in the myocyte, T-test analysis not identify any statistical difference due to the high variability of the data.

### EXAMPLE 6

#### Hexahistidine tagged penetratin

15 A number of DNA constructs were generated for producing hexahistidine (H6) tagged penetratin and penetratin-PLB recombinant proteins in bacteria. Using a commercially available expression vector, pRSET (Invitrogen), recombinant protein H6-ANT (Seq. ID. No. 16) was generated. While this recombinant protein has no PLB attached, it was  
20 engineered to have epitope tags which was used to detect the protein as it entered the heart. A variation of H6-ANT was also expressed containing the PLB sequence, H6-wtPLB-ANT (Seq. ID. No. 17), in addition to an H6-PLB(S16E mutant)-ANT protein and an H6-PLB (V49A mutant)-ANT protein (Seq. ID. Nos. 18 and 19 respectively). H6-beta-galactosidase-  
25 ANT, H6-TAT, and H6-beta-galactosidase-TAT were also expressed at lower levels (seq. not listed). A non-functional ANT-penetratin with two mutations at residues 68 and 67, where Trp was mutated to Phe were made as negative control for the other three penetratin-PLB proteins.

To measure the effect these recombinant penetratin-based proteins  
30 have on cardiac contraction, one mouse was injected intraperitoneally

-32-

with 2 mg of the H6-ANT peptide. A second mouse was injected intraperitoneally with 2 mg of the H6-ANT mutant protein. After a 3 hour incubation period, the mice were sacrificed and the hearts removed for analysis. The blood in the heart was removed by forcing fluid backwards through the aortic arch. Each heart was dissected into atrial tissue, left ventricular tissue, and right ventricular tissue. All the tissue was washed extensively in a physiologically balanced PBS solution and flash frozen in liquid nitrogen. The tissue were then lysed in 8 M Urea, 2% triton-X100, for 10 minutes and equal amounts of the supernatants were electrophoresed on 15% PAGE. The bands were transferred to a PVDF membrane. The membranes were labeled with anti-His antibody in order to identify if the lysate contained the epitope tagged protein.

The invention disclosed herein provides several methods for the treatment of heart failure through the inhibition or alteration of the interaction between phospholamban and sarcoplasmic reticulum  $\text{Ca}^{2+}$  - ATPase within the cardiomyocytes. Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

-33-

What is claimed is:

1. A method for treatment of heart failure comprising inducing phospholamban deficiency.

2. The method for treatment of heart failure of claim 1, wherein  
5 an exogenous phospholamban protein induces phospholamban deficiency.

3. The method for treatment of heart failure of claim 2, wherein the exogenous phospholamban protein is selected from the group consisting of mutations of PLB, sense PLB, antisense PLB, truncated PLB, native PLB, and antibody against PLB.

10 4. The method for treatment of heart failure of claim 3, wherein the mutations of PLB comprise point mutations of PLB.

5. The method for treatment of heart failure of claim 3, wherein the antibody against PLB comprises contractilin.

6. A peptide based therapeutic agent for inhibiting  
15 phospholamban activity consisting of a first peptide and a second peptide as a complex, wherein the first peptide comprises a transport peptide and the second peptide comprises a cargo peptide.

7. The peptide based therapeutic agent of claim 6, wherein the transport peptide is selected from the group consisting of penetratin,  
20 adenovirus , bacterial and lipid vesicle based transport peptide.

8. The peptide based therapeutic agent of claim 6, wherein the cargo peptide is selected from the group consisting of mutations of PLB, sense PLB, antisense PLB, truncated PLB, and native PLB protein.

9. The peptide based therapeutic of claim 6, wherein the first  
25 peptide transports the second peptide across a cell membrane.

10. The peptide based therapeutic of claim 6, wherein the first peptide and the second peptide are linked by a covalent linkage.

11. The peptide based therapeutic of claim 10, wherein the covalent linkage consists of a branched polylysine backbone, a single  
30 peptide bond, or a disulfide bond.

-34-

12. A method for treatment of heart failure comprising enhancement of cardiac contractility by inhibition of PLB-SERCA2a interaction.

13. The method of claim 12, wherein the cardiac contractility is enhanced by inhibiting effect of PLB on sarcoplasmic reticulum  $\text{Ca}^{2+}$  ATPase.

14. The method of claim 12, wherein an exogenous phospholamban protein is used to inhibit phospholamban deficiency.

15. The method of claim 14, wherein the exogenous phospholamban protein is selected from the group consisting of mutations of PLB, sense PLB, antisense PLB, truncated PLB, native PLB, and antibody against PLB.

16. The method of claim 15, wherein the mutations of PLB comprise point mutations of PLB.

17. The method for treatment of heart failure of claim 15, wherein the antibody against PLB comprises contractilin.




Fig. 1



Fig. 2a




Fig. 2b




Fig. 2c




Fig. 2d




Fig. 2

3/10

Fig. 2e




Fig. 2f




Fig. 2g




Fig. 2h




Fig. 2




Fig. 3a

Fig. 3b




Fig. 3c




Fig. 3d




Fig. 3




Fig. 3 e




Fig. 4a


**b****Fig. 4b**

Fig. 5

Fig. 5a




Fig. 5b

	control n=7	wildtype PLB n=3	V49A mutant PLB n=4
Shortening (%)	7.20 ± 0.60	3.50 ± 0.24 *	11.45 ± 0.88 **
-dL/dt (mm)	88.4 ± 10.3	48.4 ± 5.9 *	150.3 ± 9.6 **†
+dL/dt (mm)	56.6 ± 6.5	28.1 ± 6.4 †	116.5 ± 13.5 **†
Cell length (μm)	104.5 ± 3.1	109.2 ± 3.9	108.7 ± 3.3

9/10

Fig. 6a




Fig. 6b




Fig. 6c




Fig. 6



10/10




Fig. 7




Fig. 8

## SEQUENCE LISTING

<110> Kenneth Chien, Wolfgang Dillman, Susumu Minamisawa,  
Huaping He, Masahiko Hoshijima, Markus Meyer, Christopher  
Scott, Yibin Wang, Gregg Silverman

<120> A METHOD FOR INHIBITION OF PHOSPHOLAMBAN  
ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE  
AND HEART FAILURE

<130> 6627-9025

<140> unknown

<141> November 2, 1999

<150> US 60/106,718

<151> November 2, 1998

<160> 9

<170> Word Perfect 8.1

<210> 1

<211> 52

<212> PRT

<213> Human Phospholamban

<220> wild type

<221> amino acid sequence

<222> 1...52

<400> 1

Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser Thr Ile  
1 5 10 15

Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe  
20 25 30 35

Cys Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu 52  
40 45 50

<210> 2

<211> 52

<212> PRT

<213> Human Phospholamban

<220> Val49Ala mutant

<221> amino acid sequence

<222> 1...52

<400> 2  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser Thr Ile  
 1 5 10 15  
 Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys  
 20 25 30 35  
 Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Ala Met Leu Leu 52  
 40 45 50

<210> 3  
 <211> 52  
 <212> PRT  
 <213> Human Phospholamban

<220> Glu2Ala mutant  
 <221> amino acid sequence  
 <222> 1...52

<400> 3  
 Met Ala Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser Thr Ile  
 1 5 10 15  
 Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys  
 20 25 30 35  
 Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu 52  
 40 45 50

<210> 4  
 <211> 52  
 <212> PRT  
 <213> Human Phospholamban

<220> Arg14Glu mutant  
 <221> amino acid sequence  
 <222> 1...52

<400> 4  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Glu Ala Ser Thr Ile  
 1 5 10 15  
 Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys  
 20 25 30 35

Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu 52  
 40 45 50

<210> 5  
 <211> 52  
 <212> PRT  
 <213> Human Phospholamban

<220> Ser16Asn mutant  
 <221> amino acid sequence  
 <222> 1...52

<400> 5  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Asn Thr Ile  
 1 5 10 15

Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys  
 20 25 30 35

Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu 52  
 40 45 50

<210> 6  
 <211> 52  
 <212> PRT  
 <213> Human Phospholamban

<220> Lys3Glu/Arg15Glu mutant  
 <221> amino acid sequence  
 <222> 1...52

<400> 6  
 Met Glu Glu Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Glu Ala Ser Thr Ile  
 1 5 10 15

Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys  
 20 25 30 35

Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu 52  
 40 45 50

<210> 7  
 <211> 16  
 <212> PRT  
 <213> Drosophila

<220> antennapedia  
 <221> amino acid sequence  
 <222> 1...16

<400> 7  
 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
 1 5 10 15

<210> 8  
 <211> 16  
 <212> PRT  
 <213> Human Phospholamban

<220> carboxy terminal  
 <221> amino acid sequence  
 <222> 1...16

<400> 8  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser  
 1 5 10 15

<210> 9  
 <211> 269  
 <212> PRT  
 <213> Contractilin

<220>  
 <221> amino acid sequence  
 <222> 1...269

<400> 9

Met His His His His His Val Ala Gln Ala Ala Leu Thr His Ser Ser Ser  
 1 5 10 15

Val Ser Ala Asn Pro Gly Glu Thr Val Lys Ile Thr Cys Ser Gly Gly Gly Asn  
 20 25 30 35

Tyr Ala Gly Ser Tyr Tyr Tyr Gly Trp Phe Gln Gln Lys Ser Pro Gly Ser Ala

40 45 50

Pro Val Thr Val Ile Tyr Ser Asn Asp Gln Arg Pro Ser Asn Ile Pro Ser Arg  
55 60 65 70

Phe Ser Gly Ser Thr Ser Gly Ser Thr Ser Thr Leu Thr Ile Thr Gly Val Arg  
75 80 85 90

Ala Glu Asp Glu Ala Val Tyr Phe Cys Gly Ser Asn Ser Gly Thr Gly Tyr Val  
95 100 105

Gly Ile Phe Gly Ala Gly Thr Thr Leu Thr Val Leu Gly Gln Ser Ser Arg Ser  
110 115 120 125

Ser Thr Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly Ala  
130 135 140

Leu Ser Leu Val Cys Arg Ala Ser Gly Phe Thr Phe Ser Arg Phe His Met  
145 150 155 160

Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Gly Ile Asp  
165 170 175

Asp Gly Gly Ser Phe Thr Leu Tyr Gly Ala Ala Val Lys Gly Arg Ala Thr Ile  
180 185 190 195

Leu Arg Asp Asn Gly Gln Ser Thr Val Arg Leu Gln Leu Asp Asn Leu Arg  
200 205 210

Pro Glu Asp Thr Ala Thr Tyr Phe Cys Val Lys Thr Lys Cys Gly Gly Asn  
215 220 225 230

Gly Trp Cys Gly Ala Asp Arg Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile  
235 240 245

Val Ser Ser Thr Ser Gly Gln Ala Gly Gln Tyr Pro Tyr Asp Val Pro Asp Tyr  
250 255 260 265

Ala Ser  
269

<210> 10  
 <211> 36  
 <212> PRT  
 <213> Human Phospholamban

<220> PLB-ANT  
 <221> amino acid sequence  
 <222> 1...36

<400> 10  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser Thr Ile  
 1 5 10 15

Glu Met Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
 20 25 30 35

<210> 11  
 <211> 35  
 <212> PRT  
 <213> Human Phospholamban

<220> TAT-PLB  
 <221> amino acid sequence  
 <222> 1...35

<400> 11

Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Met Glu  
 1 5 10 15

Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser Thr Ile Glu Met  
 20 25 30 35

<210> 12  
 <211> 36  
 <212> PRT  
 <213> Human Phospholamban

<220> Ser16Glu PLB mutant-ANT  
 <221> amino acid sequence  
 <222> 1...36

<400> 12

Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Glu Thr Ile  
 1 5 10 15

Glu Met Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
 20 25 30 35

<210> 13  
 <211> 35  
 <212> PRT  
 <213> Human Phospholamban

<220> TAT- Ser31Glu PLB mutant  
 <221> amino acid sequence  
 <222> 1...35

<400> 13  
 Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Met Glu  
 1 5 10 15

Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Glu Thr Ile Glu Met  
 20 25 30

<210> 14  
 <211> 16  
 <212> PRT  
 <213> Drosophila

<220> ANT  
 <221> amino acid sequence  
 <222> 1...16

<400> 14  
 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
 1 5 10 15

<210> 15  
 <211> 11  
 <212> PRT  
 <213> HIV

<220> TAT  
 <221> amino acid sequence  
 <222> 1...11



<400> 15  
 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
 1 5 10

<210> 16  
 <211> 61  
 <212> PRT  
 <213> E. coli

<220> H6-ANT  
 <221> amino acid sequence  
 <222> 1...61

<400> 16  
 Met Arg Gly Ser His His His His His Gly Met Ala Ser Met  
 1 5 10 15

Thr Gly Gly Gln Gln Met Gly Arg Asp Leu Tyr Asp Asp Asp Asp  
 20 25 30

Lys Asp Pro Ser Ser Arg Ser Ala Ala Gly Thr Met Glu Phe Arg  
 35 40 45

Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
 50 55 60

Ala  
 61

<210> 17  
 <211> 79  
 <212> PRT  
 <213> E. coli

<220> H6-wtPLB-ANT  
 <221> amino acid sequence  
 <222> 1...79

<400> 17  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala  
 1 5 10 15

Ser Thr Ile Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn  
 20 25 30

Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu Ile  
                   35                  40                  45

Cys Ile Ile Val Met Leu Leu His His His His His His Lys Gly  
                   50                  55                  60

Glu Phe Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys  
                   65                  70                  75

Trp Lys Lys Ala  
                   79

<210> 18

<211> 79

<212> PRT

<213> E. coli

<220> H6-PLB (Ser16Glu mutant)-ANT

<221> amino acid sequence

<222> 1...79

<400> 18

Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala  
   1                  5                  10                  15

Glu Thr Ile Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn  
                   20                  25                  30

Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu Ile  
                   35                  40                  45

Cys Ile Ile Val Met Leu Leu His His His His His His Lys Gly  
                   50                  55                  60

Glu Phe Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys  
                   65                  70                  75

Trp Lys Lys Ala  
                   79

<210> 19

<211> 79  
<212> PRT  
<213> E. coli  
  
<220> H6-PLB (Val49Ala mutant)-ANT  
<221> amino acid sequence  
<222> 1...79

<400> 19  
Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala  
1 5 10 15

Ser Thr Ile Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn  
20 25 30

Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu Ile  
35 40 45

Cys Ile Ile Ala Met Leu Leu His His His His His Lys Gly  
50 55 60

Glu Phe Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys  
65 70 75

Trp Lys Lys Ala  
79

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 38/17, 47/48, C07K 17/00,</b> <b>A61P 9/04</b>		<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/25804</b> <b>(43) International Publication Date:</b> 11 May 2000 (11.05.00)
<b>(21) International Application Number:</b> PCT/US99/25692 <b>(22) International Filing Date:</b> 2 November 1999 (02.11.99) <b>(30) Priority Data:</b> 60/106,718 2 November 1998 (02.11.98) US 60/145,883 27 July 1999 (27.07.99) US <b>(71) Applicant (for all designated States except US):</b> THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 9500 Gilman Drive, Mail Code 0910, La Jolla, CA 93093-0910 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> CHIEN, Kenneth [US/US]; 9500 Gilman Drive, Mail Code 0613-C, Basic Science Building 5020, La Jolla, CA 92093-0613-C (US). DILLMAN, Wolfgang [US/US]; 9500 Gilman Drive, Mail Code 0613-C, La Jolla, CA 92093-0613-C (US). MINAMISAWA, Susanne [US/US]; 9500 Gilman Drive, Mail Code 0613-C, Basic Science Building 5027, La Jolla, CA 92093-0613-C (US). HE, Huaping [US/US]; 9500 Gilman Drive, Mail Code 0613-C, La Jolla, CA 92093-0613-C (US). HOSHIJIMA, Masahiko [US/US]; 9500 Gilman Drive, Mail Code 0613-C, Basic Science Building 5027, La Jolla, CA 92093-0613-C (US). MEYER,			<b>(74) Agents:</b> MUSICK, Eleanor, M. et al.; Brown, Martin, Haller & McClain, 1660 Union Street, San Diego, CA 92101-2926 (US). <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
			<b>Published</b> With international search report. <b>(88) Date of publication of the international search report:</b> 5 October 2000 (05.10.00)
<b>(54) Title:</b> A METHOD FOR INHIBITION OF PHOSPHOLAMBAN ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE AND HEART FAILURE			
<b>(57) Abstract</b> <p>The present invention provides a method for the treatment of heart failure through the use of small peptide complexes and recombinant proteins which function to enhance contractility in failing hearts and reduce blood pressure in individuals with hypertension by inhibiting the interaction between phospholamban and sarcoplasmic reticulum Ca<sup>2+</sup> ATPase (SERCA2a) within cardiomyocytes. In addition, a means is provided for the transport of such therapeutic agents into the cytoplasm and nucleus of cardiomyocytes.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 May 2000 (11.05.2000)

PCT

(10) International Publication Number  
WO 00/25804 A3

(51) International Patent Classification<sup>7</sup>: A61K 38/17,  
47/48, C07K 17/00, A61P 9/04

92093-0613-C (US). SILVERMAN, Gregg, J. [US/US];  
9500 Gilman Drive, Mail Code 0613-C, La Jolla, CA  
92093-0613-C (US).

(21) International Application Number: PCT/US99/25692

(22) International Filing Date:  
2 November 1999 (02.11.1999)

(74) Agents: MUSICK, Eleanor, M. et al.; Brown, Martin,  
Haller & McClain, 1660 Union Street, San Diego, CA  
92101-2926 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/106,718 2 November 1998 (02.11.1998) US  
60/145,883 27 July 1999 (27.07.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): THE  
REGENTS OF THE UNIVERSITY OF CALIFORNIA  
[US/US]; 9500 Gilman Drive, Mail Code 0910, La Jolla,  
CA 93093-0910 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CHIEN, Kenneth  
[US/US]; 9500 Gilman Drive, Mail Code 0613-C, Basic  
Science Building 5020, La Jolla, CA 92093-0613-C  
(US). DILLMAN, Wolfgang [US/US]; 9500 Gilman  
Drive, Mail Code 0613-C, La Jolla, CA 92093-0613-C  
(US). MINAMISAWA, Susanne [US/US]; 9500 Gilman  
Drive, Mail Code 0613-C, Basic Science Building  
5027, La Jolla, CA 92093-0613-C (US). HE, Huaping  
[US/US]; 9500 Gilman Drive, Mail Code 0613-C, La  
Jolla, CA 92093-0613-C (US). HOSHIIJIMA, Masahiko  
[US/US]; 9500 Gilman Drive, Mail Code 0613-C, Basic  
Science Building 5027, La Jolla, CA 92093-0613-C  
(US). MEYER, Markus [US/US]; 9500 Gilman Drive,  
Mail Code 0613-C, La Jolla, CA 92093-0613-C (US).  
SCOTT, Christopher [US/US]; 9500 Gilman Drive,  
Mail Code 0613-C, Basic Science Building 5033, La  
Jolla, CA 92093-0613-C (US). WANG, Yibin [US/US];  
9500 Gilman Drive, Mail Code 0613-C, La Jolla, CA

Published:

— with international search report

(88) Date of publication of the international search report:  
5 October 2000

(48) Date of publication of this corrected version:  
6 December 2001

(15) Information about Correction:  
see PCT Gazette No. 49/2001 of 6 December 2001, Section  
II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: A METHOD FOR INHIBITION OF PHOSPHOLAMBAN ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE AND HEART FAILURE

(57) Abstract: The present invention provides a method for the treatment of heart failure through the use of small peptide complexes and recombinant proteins which function to enhance contractility in failing hearts and reduce blood pressure in individuals with hypertension by inhibiting the interaction between phospholamban and sarcoplasmic reticulum  $\text{Ca}^{2+}$  ATPase (SERCA2a) within cardiomyocytes. In addition, a means is provided for the transport of such therapeutic agents into the cytoplasm and nucleus of cardiomyocytes.



WO 00/25804 A3

-1-

## **A METHOD FOR INHIBITION OF PHOSPHOLAMBAN ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE AND HEART FAILURE**

This application claims the benefit of priority of United States  
5 Provisional Application Serial No. 60/106,718, filed November 2, 1998  
and United States Provisional Application Serial No. 60/145,883, filed  
July 27, 1999, both of which are incorporated herein by reference in their  
entirety.

### **BACKGROUND OF THE INVENTION**

#### **FIELD OF THE INVENTION**

This invention relates generally to a method for the treatment of  
heart failure, and more specifically to the inhibition of phospholamban  
(PLB) activity for the treatment of myocardial dysfunction.

### **BACKGROUND INFORMATION**

Heart failure is the leading cause of combined morbidity and  
mortality in the United States and other developed countries. Congestive  
heart failure is characterized by a reduced contraction and delayed  
20 relaxation of the heart however, fundamental molecular mechanisms  
which drive the patho-physiological pathways for congestive heart are  
largely unknown. Current therapy for the heart disease is primarily  
palliative and is not targeted to the underlying biological pathways which  
are thought to lead to the initiation and progression of cardiac muscle  
25 dysfunction.

Heart muscle failure is a complex, integrative, multi-factorial disease  
in which the genetic pathways that confer susceptibility are interwoven  
with the environmental stimulus of biomechanical stress that accompanies  
heart injury, pressure and volume overload, and genetic defects in  
30 components of the cytoskeleton. In response to this biomechanical

-2-

stress, a series of parallel and converging signaling pathways are activated that lead to the adaptive response of compensatory hypertrophy.

Subsequently, there can be a transition to chamber dilation and pump failure that is associated with a loss of viable myocytes, a decrease in contractile elements, myofilament disarray and interstitial fibrosis.

Recently, the activation of signal transduction pathways which trigger the onset of programmed cell death have been implicated in promoting the pathological transition to heart failure, as well as a gp130 dependent myocyte survival pathway that can block the actions of the pro-apoptotic pathways and prevent the early onset of heart failure and cardiomyopathy. In addition to these extrinsic stress-related pathways for myocyte adaptation, there also must be intrinsic signaling pathways that lead to the impairment of cardiac excitation-contraction (EC) coupling and associated severe defects in cardiac contractile performance that are the clinical hallmarks of the progression of the heart failure phenotype.

The sarcoplasmic reticulum (SR) plays an integral role in the coordination of the movement of cytosolic  $\text{Ca}^{2+}$  throughout the cardiac tissue. In separate studies by Mercadier, *et al.* (*J. Clin. Invest.*, 1990; 85:305-309), Arai, *et al.* (*Circ. Res.*, 1993; 72:463-469), de la Bastie, *et al.* (*Circ. Res.*, 1990; 66:554-564), and Feldman, *et al.* (*Circ. Res.*, 1993; 73:184-192), research on human failing hearts and animal models of heart failure have suggested that the reduced uptake the cytosolic  $\text{Ca}^{2+}$  by the SR is responsible for prolonged diastolic relaxation.  $\text{Ca}^{2+}$  stored in the SR is released into the cytosol to activate the contraction of cardiac muscle and subsequently re-accumulated to achieve relaxation. Activity of the cardiac SR  $\text{Ca}^{2+}$  ATPase (SERCA2a) is the rate determining factor of  $\text{Ca}^{2+}$  re-uptake into the SR, and SERCA2a activity is itself regulated by phospholamban, a 52-amino acid muscle-specific SR phosphoprotein.

Phospholamban (PLB) was first identified as a major phosphorylation target in the SR membrane in research by Tada, *et al.* (*J.*



-3-

*Bio./ Chem.*, 1974; 249:6174-6180) and appeared to be a potent inhibitor of SERCA2a activity in its unphosphorylated form. The inhibitory effect of PLB on SERCA2a is reduced by an increase in intracellular calcium or by the phosphorylation of PLB in response to  $\beta$ -adrenergic stimulation. PLB exists primarily in a pentameric form, that when subjected to high temperature, dissociates into five equivalent monomers.

The amino acids of monomeric PLB are grouped into three physical and functional domains. Domains Ia and II are rich in  $\alpha$ -helices and are connected by the less structured domain Ib. Domain Ia is composed of amino acids 1-20, the majority of which are in an  $\alpha$ -helical confirmation, having a net positive charge. Domain Ib consists of amino acid residues 21-30 and constitutes the cytoplasmic sector of the monomer. Domain II amino acids 31-52, represents the transmembrane sector and is made up solely of uncharged residues that are responsible for stabilizing the pentamer formation.

PLB is a mediator in the regulation of myocardial function by catecholamines through the cAMP cascade. Ser (16) and Thr (17), in domain Ia are the confirmed binding sites for cAMP-dependent protein kinase (PKA) and Ca/calmodulin-dependent protein kinase, respectively, which function to catalyze phosphoester phosphorylation of PLB which in turn relieves its inhibition on SERCA2a activity. Because Ser (16) and Thr (17) can be phosphorylated by the kinases, the net charge of the amino acids can be shifted from positive to neutral and even to negative. Together with the charged residues of SERCA2a, the shifting of charges in domain Ia of PLB can result in profound alterations in the protein-protein interaction of the PLB-SERCA2a system. Domain II also contains some key amino acids for functional expression of PLB, in that amino acids of one face of the domain II helix are associated with the transmembrane domain of SERCA2a.

There may be two ways in which PLB regulates  $\text{Ca}^{2+}$ -ATPase

-4-

activity: 1) a quick-acting, short-term mechanism involving PLB phosphorylation and depression of calcium pumping activity, and 2) a slower acting but longer term process involving a change in the molecular ratio of PLB to the  $\text{Ca}^{2+}$ -ATPase brought about by control of gene expression. Under physiological conditions, phosphorylation at Ser (16) by PKA is the predominant event that leads to proportional increases in the rate of  $\text{Ca}^{2+}$  uptake to the SR and accelerates ventricular relaxation. An increase in the relative ratio of PLB to SERCA2a is an important determinant of SR dysfunction in both experimental and human heart failure. Moreover, attenuated PLB phosphorylation by PKA may be responsible for impaired diastolic function and prolonged  $\text{Ca}^{2+}$  transients in failing hearts by which the  $\beta$ -adrenergic receptor-cAMP system is severely down-regulated by enhanced sympathetic tone.

A detailed mutagenesis study by Toyofuku, *et al.* (*J. Biol. Chem.*, 1994; 269:3088-3094) revealed that several amino acids in the cytoplasmic domain of PLB are important for its inhibitory function. The study showed that when the certain amino acids were mutated into amino acids of different charge, the PLB mutants lost their inhibitory effect on the co-transfected SERCA2 in HEK293 cells. However, it is still unclear whether PLB bearing these mutants can exert dominant negative effects on endogenous wild-type PLB and consequently stimulate endogenous SERCA2a in cardiac myocytes. Additionally, it is unclear how the mechanisms of transfer of these PLB point mutations into cardiomyocytes breach the cytoplasmic membrane barrier in order to effect endogenous SERCA2a activity.

Genetically based mouse models of dilated cardiomyopathy by Arber, *et al.* (*Cell*, 88:393-403; 1997) provide evidence that chamber dilation and the progression to heart failure is dependent on a specific  $\text{Ca}^{2+}$  cycling defect in the cardiac sarcoplasmic reticulum. In the mouse models, ablation of phospholamban (PLB) rescued the spectrum of

-5-

structural, functional, and molecular phenotypes that resemble heart failure. Furthermore, release of the phospholamban-SERCA2a interaction through the forced *in vivo* overexpression of a PLB point mutation dominantly activated the contractility of ventricular muscle cells. Thus, there is the possibility that interfering with the PLB-SERCA2a interaction may provide a novel therapeutic approach for preventing heart failure.

There is the understanding that interfering with the PLB-SERCA2a interaction may be a potential therapeutic target for the treatment of heart failure, however, the internalization of exogenous molecules to enhance cardiac contractility by live myocytes remains an unsolved issue. A means must be available to deliver any therapeutic agent directly to the cytoplasm and nucleus of cardiac myocytes. Penetratins, a class of peptides with translocating properties, have the ability to carry hydrophilic compounds across the plasma membrane. Research by Schwarze, *et al.* (*Science* 285:1569-1572; 1999) has demonstrated an approach to protein transduction using a penetratin-based fusion protein which contains an NH<sub>2</sub>-terminal 11- amino acid protein transduction domain from the denatured HIV TAT protein (Genebank Accession No. AF033819) . Using this non-cell-type specific transfer system allows direct targeting of oligopeptides and oligonucleotides to the cytoplasm and nucleus. One of the most well characterized translocation peptides is one that corresponds to residues 43 to 58 of antennapedia, a *Drosophila* transcription factor. It is believed that the translocation peptide interacts with charged phospholipids on the outer side of the cell membrane. Destabilization of the bilayer results in the formation of inverted micelles containing the peptide that travels across the cell membrane and eventually open on the cytoplasmic side. While the use of transport peptides to move cargo molecules into cells is not novel, it has not been demonstrated that transport peptides work well in cardiomyocytes.

Thus the need remains for methods for the inhibition of PLB through

-6-

the use of mutants or small molecule inhibitors of PLB in order to manipulate the PLB/SERCA2a interaction in cardiac myocytes, as well as a transport means for these mutants or small molecule inhibitors of PLB to cross sarcoplasmic reticulum membrane barriers into the cytoplasm of cardiac myocytes for the treatment of cardiac disease and heart failure. The present invention satisfies these needs and provides related advantages as well.

### **SUMMARY OF THE INVENTION**

It is an advantage of the present invention to provide methods for treatment of heart failure by inhibiting the effect of phospholamban on  $\text{Ca}^{2+}$  uptake in cardiac tissue.

It is another advantage of the present invention to provide both small peptide complexes and recombinant proteins which function to enhance contractility in failing hearts and reduce blood pressure in individuals with hypertension by inhibiting the interaction between phospholamban and sarcoplasmic reticulum  $\text{Ca}^{2+}$  ATPase (SERCA2a) within cardiomyocytes.

It is yet another advantage of the present invention to provide for a family of compounds that consist of a transport peptide covalently attached to wild-type, mutant, or truncated PLB.

In a first exemplary embodiment of the present invention, recombinant adenoviruses are engineered which force the expression of wild-type or mutant forms of PLB which have the ability to selectively interrupt the normal inhibitory interaction between PLB and SERCA2a and in turn dominantly activate cardiac contractility.

In a second exemplary embodiment of the present invention, contractilin, a recombinant adenoviral mutant of PLB (K3E/R14E), binds to and imitates phosphorylation of phospholamban. This leads to an activation of the calcium pump of the sarcoplasmic reticulum thus

-7-

increasing cardiac contractility.

In a third exemplary embodiment of the present invention, a compound consisting of a fusion of 1) a 16-residue transport peptide and 2) a truncated phospholamban protein or similar peptide are transported across the cell membranes in a receptor independent manner. Once inside the cytoplasm of the cardiomyocyte, the truncated phospholamban or similar peptide act as a competitive inhibitor of endogenous phospholamban interactions with SERCA2a.

### **BRIEF DESCRIPTION OF DRAWINGS**

Figure 1 is an illustration diagramming a working model for the role of the PLB-SERCA2a interaction in the progression of heart failure.

Figure 2 shows the hemodynamic analysis of rescue of in vivo cardiac dysfunction in DKO mice (a-d) and hemodynamic assessment of  $\beta$ -adrenergic response to progressive infusion of dobutamine (e-h), where Figure 2a shows the plot for maximal first derivative of LV pressure, LV dP/dtmax. Figure 2b shows the plot for minimal first derivative of LV pressure, LV dP/dtmin. Figure 2c shows the plot for Lv end diastolic pressure. Figure 2d shows the plot for Tau. Figure 2e shows a graph of maximal first derivative of LV pressure, LV dP/dtmax. Figure 2f shows a graph of minimal first derivative of LV pressure, LV dP/dtmin. Figure 2g shows a graph of Lv end diastolic pressure. Figure 2h shows a graph of heart rate.

Figure 3 shows plotted data from the analysis of rescue of physiological calcium signaling defects in DKO myocytes, where Figure 3a is a series of graphs of representative intracellular  $\text{Ca}^{2+}$  transient in WT, MLPKO and DKO myocytes. Figure 3b is a bar graph of the amplitude of  $\text{Ca}^{2+}$  transients. Figure 3c is a bar graph of intracellular diastolic  $\text{Ca}^{2+}$  concentration. Figure 3d is a bar graph of SR  $\text{Ca}^{2+}$  content. Figure 3e is the immunoblot of MLP deficiency.

-8-

Figure 4a shows a dot blot analysis of rescue of embryonic gene markers of the heart failure phenotype in DKO mice. Figure 4b is a bar graph comparing the relative induction of mRNA for wild-type, MLPKO, and DKO myocytes.

5           Figure 5 illustrates the inhibition of the interaction between PLB and SERCA2a, where Figure 5a is a series of graphs which plot the length change in myocytes. Figure 5b is a summary of the data of cell length changes.

10           Figures 6a is a Western blot analysis of myocytes containing the adenovirus transgenes expressing sense PLB (sPLB), antisense PLB (asPLB), E2A, R14E, S16N, and K3E/R14E against monoclonal PLB. Figure 6b is a Western blot showing the results of cell infectivity by PLB, sPLB and K3E/R14E. Figure 6c illustrates the Western blot analysis of PLB infectivity of Sol8 cells.

15           Figure 7 shows a plot of SR Ca<sup>2+</sup> uptake in homogenates of neonatal rat cardiomyocytes infected with adenovirus expressing the indicated genes.

Figure 8 shows a plot of the data derived from indo 1 fluorescence-facilitated Ca<sup>2+</sup> transients of myocytes.

20

#### **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

To directly assess the role Ca<sup>2+</sup> cycling defects play in the transition to heart failure, cardiomyopathy in muscle-specific LIM protein (MLP)-deficient mice can be reversed by removing the gene that codes for PLB. Mice which harbor an ablation of MLP show many of the phenotypic features of human dilated cardiomyopathy at the molecular, cellular, and physiological levels. A uniform feature of end-stage dilated cardiomyopathy is a marked increase in cardiac wall stress that is accompanied by thinning of the chamber wall and an accompanying decrease in cardiac contractility and relaxation. Because calcium cycling is critical for both

25

30

-9-

cardiac relaxation and contractility, defects in the pathway that control calcium uptake and release from the sarcoplasmic reticulum are prime candidates for driving the progression of heart failure.

The creation of mice which harbor a deficiency in PLB, in addition to MLP, exhibit rescue from all the phenotypic characteristics of human heart failure normally found in MLP single knock-out (MLPKO) mice. To determine whether the functional benefits associated with PLB ablation in MLPKO mice specifically reflect the loss of the direct interaction between PLB and SERCA2a, the applicant of the present invention has engineered point mutations in the PLB gene which interrupt the functional inhibitory interaction between PLB and SERCA2a. Through the creation of recombinant adenoviruses encoding point mutations in PLB, it is demonstrated that progressive defects in excitation-contraction coupling in heart failure are related to the enhanced inhibition of SERCA2a by PLB and that the introduction of phospholamban deficiency into the setting of a transgenic model of cardiac hypertrophy results in rescued cardiac function. These results are independently supported by the fact that MLP-deficient mice harboring a transgene which directs cardiac specific overexpression of SERCA2a also exhibit rescue of the cardiomyopathy phenotype. Taken together, these results provide clear evidence that sarcoplasmic reticulum calcium cycling is critical to the progression of heart failure and points to the critical regulatory role of PLB inhibition of SERCA2a activity in the progression of heart failure. This, in turn, pinpoints the possibility of PLB as a key therapeutic target.

Further study of the MLP-PLB knock-out (DKO) mice indicated that the induction of PLB deficiency in the setting of cardiomyopathic mutation can result in maximal stimulation of cardiac contractile performance. The contractility of the DKO hearts at baseline levels was comparable to the contractility of wild-type hearts following maximal  $\beta$ -adrenergic stimulation. This result suggests that following the removal of the tonic

-10-

inhibition of SR calcium pump function by PLB, there is essentially a "supra-rescue" in terms of cardiac contractile function of the cardiomyopathic heart. Since PLB is a direct substrate for phosphorylation by both cyclic AMP-dependent protein kinase A and calcium/calmodulin dependent kinase, the regulation of cardiac contractility by cAMP-dependent stimuli may occur via the phosphorylation of PLB, which in turn prevents the inhibitory interaction with SERCA2a.

According to the theory behind the phosphorylation of PLB, the "supra-rescue" of the cardiomyopathic MLP-deficient mice to super-normal levels in the setting of PLB-deficiency might simply reflect the removal of the rate limiting step in the tonic inhibition of cardiac contractility. Consistent with this rationale, studies by Rockman, *et al.* (*Proc. Natl. Acad. Sci. USA* 95:7000-7005; 1998) have documented that relief of  $\beta$ -adrenergic desensitization in the MLP-deficient mice can also lead to significant rescue of the dilated cardiomyopathic phenotype. Since PLB is an SR protein that interacts with at least three regulatory components (cAMP-dependent protein kinase, calcium/calmodulin-dependent kinase, and protein phosphatase), it should be determined whether the dominant effect of PLB ablation on improving cardiac contractile performance reflects the chronic interaction of PLB with the SERCA2a or whether this rescue effect is related to the interaction of PLB with other known or novel cardiac proteins.

Utilizing recombinant adenoviruses which force the expression of wild-type and mutant forms of PLB, the present invention provides for point mutations in PLB that can selectively interrupt the normal inhibitory interaction between PLB and SERCA2a and can dominantly activate cardiac contractility in cardiac ventricular muscle cells in the absence of catecholamine. Figure 1 outlines the mechanism responsible for the rescue effect observed in the DKO mice. Both PLB and MLP are muscle-specific proteins, and as such, there must be a muscle cell autonomous



-11-

pathway that is required for the progression and the rescue of the phenotype, as opposed to extrinsic stress signals that promote or suppress myocyte survival pathways. Since PLB and MLP do not directly interact at the protein level, eliminating direct interaction between PLB and MLP as the basis for rescue, there must be a physiological as opposed to biochemical regulatory pathway that links the PLB regulatory pathways with the onset of dilated cardiomyopathy. As shown in Figure 1, in the normal heart, SR-calcium stores are maintained through the activity of the SERCA2a which leads to an uptake of calcium into the SR and consequent maintenance of normal cardiac relaxation and reduction in wall stress. Subsequently, SR release of calcium, via the calcium release channel, results in normal quantal calcium release and the consequent activation of the cardiac myofilaments leading to myocardial contraction. Accordingly, enhanced  $\text{Ca}^{2+}$  content in the SR leads to an enhanced  $\text{Ca}^{2+}$  release with a corresponding increase in cardiac contractility.

The activity of SERCA2a is regulated by the inhibitory effects of the direct interaction of PLB with SERCA2a, which can be relieved by the cAMP-dependent phosphorylation of PLB following the delivery of  $\beta$ -adrenergic stimuli. In the setting of heart failure, there is a relative decrease in SERCA2a function due to an inhibitory effect of PLB that arises due to blunted  $\beta$ -adrenergic responsiveness. As a result, there is less phosphorylation of PLB and a constitutive inhibition of SERCA2a, via chronic interaction with PLB, leading to a relative decrease in SR calcium content versus normal levels. This decrease in calcium stores is translated into a decrease in the quantal release of calcium through the calcium release channel and a consequent decrease in the single cell calcium transients and *in vivo* cardiac contractility. In the DKO mice, the inhibitory effect of PLB is removed, as shown in Figure 1, thereby relieving the system from the downstream inhibitory effects of PLB on the SR calcium pump, resulting in maintenance of SR calcium uptake and

-12-

reduction of wall stress towards normal levels. At the same time, this increase in SR calcium content results in maintenance of normal calcium quantal release, thereby leading to maintenance of normal contractility and relaxation.

5

*Muscle-specific LIM protein knock-out and Double knock-out mice*

Tests of the present invention were conducted using a double knock-out (DKO) mouse model which harbors homozygous ablation of two independent muscle specific genes. For this strategy, PLB knock-out (PLBKO) mice are mated into the background of MLP knock-out (MLPKO) mice which harbor molecular, structural and physiological features of the complex *in vivo* heart failure phenotype of dilated cardiomyopathy. The F3 generation of these mice are used for the actual experimentation to eliminate any potential background effects from either the PLBKO or MLPKO line on the observed cardiac phenotype of the DKO line.

MLPKO mice display a marked increase in heart/body weight ratio ( $6.34 \pm 0.22$  mg/g,  $n=8$ ) versus age and gender matched wild-type mice ( $4.60 \pm 0.21$  mg/g,  $n=7$ ;  $p<0.001$ ). The heart/body weight ratio in DKO mice ( $5.13 \pm 0.19$  mg/g,  $n=9$ ) is significantly smaller than that of MLPKO mice ( $p<0.01$ ) and is not statistically different from wild-type. To evaluate whether the decreased heart weight in DKO mice is associated with amelioration of the disrupted cytoskeletal phenotype observed in MLPKO mice, electron microscopic analysis is made of hearts from MLPKO and DKO littermates. Ablation of PLB in the background of MLP<sup>-/-</sup> rescues the wide spectrum of ultrastructural defects originally observed in the MLP deficient hearts, including myofibrillar disarray and massive fibrosis. These data suggest that ablation of PLB prevents not only the increase in total heart mass, but also prevents the disorganization of cardiomyocyte cytoarchitecture and fibrosis in MLPKO cardiomyopathic mice.

-13-

To evaluate whether the marked decreases observed in *in vivo* global cardiac function is rescued in DKO mice, echocardiography is performed with age-matched littermates. As noted in Table 1, prevention of ventricular dilation is confirmed in DKO mice. MLPKO mice have enlarged cardiac chambers, as revealed by increased left ventricular end-diastolic dimensions (LVEDD) and end-systolic dimensions (LVESD), whereas DKO mice have LVEDD in the normal range. The percent fractional shortening (%FS) and mean velocity of circumferential fiber shortening (mean Vcf), indicators of systolic cardiac function, are improved in age-matched DKO littermates, also noted in Table 1. When compared to non-littermate wild-type mice as controls, most of the echocardiographic data in DKO mice are similar to those in wild-type mice, although %FS is slightly decreased in DKO mice. Furthermore, cardiac function of DKO mice remain in the normal range beyond 6 months of age (n = 2). Despite the reduction of chamber dilation, there appears to be some hypertrophy in DKO hearts. The ratio of LVEDD to LV posterior wall thickness is markedly decreased in DKO mice, indicating that the wall stress of DKO mice is reduced in comparison to MLPKO or wild-type mice. These results indicate that global cardiac function of DKO mice is preserved in the range comparable to the parameters of control hearts. It should be noted that mice which are heterozygous for PLB deficiency display an intermediate level of functional rescue versus the MLPKO and DKO mice, suggesting that partial ablation of PLB can lead to significant functional improvement of the heart failure phenotype in MLPKO mice.

-14-

Table 1

## Echocardiographic assessment

	MLPKO n = 12	MLPKO/PLBhet n = 12	DKO n = 10	wild-type n = 10
5				
LVEDD (mm)	4.87 ± 0.14	4.10 ± 0.15***	3.75 ± 0.12***	3.89 ± 0.11***
LVESD (mm)	3.94 ± 0.18	3.06 ± 0.22***†	2.60 ± 0.10***	2.44 ± 0.07***
FS(%)	19.4 ± 1.7	26.2 ± 3.2*‡	30.6 ± 1.8***†	37.2 ± 1.4***
SEp <sub>th</sub> (mm)	0.68 ± 0.05	0.86 ± 0.05*‡	0.83 ± 0.05*‡	0.64 ± 0.01
Pw <sub>th</sub> (mm)	0.67 ± 0.05	0.86 ± 0.05*‡	0.81 ± 0.04*†	0.64 ± 0.06
10				
LVEDD/ Pw <sub>th</sub> (mm/mm)	7.47 ± 0.30	5.00 ± 0.47***	4.74 ± 0.30***	6.14 ± 0.18*
mean V <sub>cf</sub> (circ/s)	3.38 ± 0.33	4.81 ± 0.73#	6.10 ± 0.41***†	4.41 ± 0.61
mean V <sub>cf</sub> c (circ/s)	1.41 ± 0.17	1.96 ± 0.27*	2.37 ± 0.13***	2.23 ± 0.10**
Heart Rate (beats/min)	351 ± 15	350 ± 15§	396 ± 13§	239 ± 14***
15				
Age (days)	65.3 ± 2.5	65.5 ± 4.5‡	67.4 ± 1.9‡	80.5 ± 1.2**
Body Weight (g)	26.7 ± 1.3	26.8 ± 0.9§	25.0 ± 1.3§	36.9 ± 2.2***

MLPKO vs. MLPKO/PLBhet or DKO or wild-type; \*: p &lt; 0.05, \*\*: p &lt; 0.01, \*\*\*: p &lt; 0.001

wild-type vs. MLPKO/PLBhet or DKO; †: p &lt; 0.05, ‡: p &lt; 0.01, §: p &lt; 0.001

MLPKO/ PLBhet vs. DKO; #: p &lt; 0.05

MLPKO mice have demonstrated a marked blunting of  $\beta$ -adrenergic responsiveness and decreased adenylyl cyclase activity. Ablation of PLB by homologous recombination in mice can augment cardiac contractile performance to a level comparable to that with maximal  $\beta$ -adrenergic stimulation of the normal heart. To confirm that the ablation of PLB can reverse the hemodynamic defects and marked  $\beta$ -adrenergic receptor desensitization associated with dilated cardiomyopathy, anesthetized mice are cardiac catheterized and assessed.

Several independent hemodynamic parameters document the rescue of the severe cardiac dysfunction with circulatory congestion to normal levels in the DKO mice. LV contractility (assessed by LV dP/dt<sub>max</sub>) and

-15-

relaxation (assessed by LV dP/dtmin) at baseline appears to be higher than that of wild-type mice and is comparable to PLBKO mice, as is shown in Figures 2a and 2b. Ablation of PLB reverses the markedly elevated LV end diastolic pressure observed in the MLPKO cardiomyopathic mice, as  
5 seen in Figure 2c.

Analysis of Figure 2d illustrates that Tau, an indicator of LV relaxation and diastolic function, are also normalized in the DKO mice, which is consistent with an improvement in wall stress. These data suggest that ablation of PLB can rescue both the systolic and diastolic  
10 dysfunction in the cardiomyopathic MLPKO mice. The blunted responses of LV dP/dtmax and LV dP/dtmin to  $\beta$ -adrenergic stimulation is observed in MLPKO mice, as shown in Figures 2e and 2f, indicating the presence of severe  $\beta$ -adrenergic desensitization in MLPKO mice. There is no stimulation of cardiac contractility (LV dP/dtmax) and relaxation (LV  
15 dP/dtmin) by dobutamine in DKO mice, as is again shown in Figures 2e and 2f. These parameters are already stimulated to their maximal levels under basal conditions in the DKO hearts.

After maximum stimulation of wild-type hearts by dobutamine, LV dP/dtmax and LV dP/dtmin are indistinguishable from these parameters in  
20 the DKO mice in the absence of any catecholamine stimulation. This evidence confirms that the interaction of PLB and SERCA2a suppresses cardiac contractility in both normal and myopathic hearts, and that inhibiting this interaction may exert a dominant effect on maximizing cardiac performance in the absence of any catecholamine stimulation.  
25 Figure 2h shows that chronotropic responsiveness to dobutamine is preserved in both DKO mice and MLPKO mice, thereby documenting the specificity of the  $\beta$ -adrenergic response to ventricular myocytes versus pacemaker cell types.

To determine the mechanisms responsible for the rescue of *in vivo*  
30 cardiac function in DKO mice, several independent parameters of  $\text{Ca}^{2+}$

-16-

signaling are assessed. It is apparent that altered  $\text{Ca}^{2+}$  homeostasis in DKO mice leads to the hemodynamic changes, intracellular  $\text{Ca}^{2+}$  transients and the expression of proteins related to  $\text{Ca}^{2+}$  cycling in the SR. MLPKO myocytes exhibit an attenuated amplitude of  $\text{Ca}^{2+}$  transients with normal levels of diastolic  $\text{Ca}^{2+}$  concentration, as is shown in Figures 3a-c. The rate of decay is slightly accelerated in MLPKO mice which suggests that a compensatory mechanism is operative during the end of  $\text{Ca}^{2+}$  uptake in MLPKO mice. Ablation of PLB is associated with a shortened duration of the  $\text{Ca}^{2+}$  transient, faster decay and preserved amplitude. Figure 3d shows that SR  $\text{Ca}^{2+}$  content is significantly decreased in MLPKO mice and increased in DKO mice as compared to wild-type mice. Quantitative immunoblotting, shown in Figure 3e, reveals that MLP deficiency is not associated with any significant alterations in protein levels of SERCA2a, PLB and calsequestrin, suggesting that the defects of  $\text{Ca}^{2+}$  cycling in MLPKO mice is based upon functional impairment of EC coupling, as opposed to simply reflecting decreases in the protein levels of either SERCA2a or phospholamban.

One of the characteristic features of heart failure is the reactivation of an embryonic gene program which may contribute to a compensatory response to an increased hemodynamic load. To confirm that hemodynamic improvement in DKO mice is accompanied by amelioration of changes at the transcriptional level, the expression of ANF,  $\alpha$ -skeletal actin, and  $\beta$ -MHC mRNAs, well established embryonic markers for heart failure, is examined. As shown in Figures 4a and 4b, ventricles of MLPKO mice display a 26-fold increase in ANF, a 13-fold increase in  $\alpha$ -skeletal actin and an 8-fold enhancement of  $\beta$ -MHC mRNAs. DKO mice exhibits only a 1.9-fold increase in ANF and no significant increase in  $\alpha$ -skeletal actin or  $\beta$ -MHC mRNAs. Thus, ablation of PLB largely suppresses induction of the embryonic gene program in MLPKO mice.

The aforementioned studies indicate that the ablation of PLB can

-17-

rescue independent parameters of heart failure and associated defects in cardiac contractility. To define the mechanism of the rescue effect, it is necessary to assess whether the chronic interaction of PLB and SERCA2a is in fact limiting for cardiac contractility in both normal and myopathic hearts. The "supra-rescue" of basal cardiac function in the DKO mice to levels comparable to those in wild-type mice following maximal catecholamine stimulation suggests that inhibition of this interaction may exert a dominant effect to maximize cardiac performance in the absence of any catecholamine stimulation.

#### *Recombinant Adenoviral transgene mutants of PLB*

Using the knowledge that certain amino acid residues of PLB are required to maintain its inhibitory effects on SERCA2a, several single point mutations of PLB, V49A (Seq. ID. No. 2), E2A (Seq. ID. No. 3), R14E (Seq. ID. No. 4), S16N (Seq. ID. No. 5), a double point mutation of PLB, K3E/R14E (Seq. ID. No. 6) and a sense and antisense PLB (Seq. ID. No. 1) transgene can be engineered in order to disrupt the inhibitory effects of PLB on SERCA2a. Using recombinant adenoviruses for *in vivo* murine cardiac gene transfer, myocytes which overexpresses V49A, one of the single point mutations in PLB, exhibit an increase in contractility, while myocytes which overexpress the wild-type PLB exhibit a decrease in contractility when compared to non-infected myocytes, as is documented in Figure 5. It can be concluded that the feasibility and utility of interfering with the interaction between the SERCA2a and PLB is clearly documented. The PLB-SERCA2a interaction appears to be the rate limiting step for establishing the set point of basal cardiac contractility and relaxation *in vivo*, and the disruption of this interaction can thereby short circuit the  $\beta$ -adrenergic pathway.

Additional Western blot analysis of myocytes containing the adenovirus transgenes expressing sense PLB (sPLB), antisense PLB

-18-

(asPLB), E2A, R14E, S16N, and K3E/R14E against monoclonal PLB antibody (Affinity BioReagents) is shown in Figure 6a. Quantification of PLB protein content, normalized to  $\alpha$ -actin for loading variance and compared with an adenovirus/ SR control lacking the transgene, shows that sPLB, E2A, and R14E mutants increase PLB protein level by 150% (PLB<sub>5</sub> + PLB<sub>1</sub>), 72 %, and 57%, respectively. In contrast, asPLB and S16N results in 54% and 33% decrease in PLB protein content within the myocytes. The introduction of K3E/R14E transgene infection of myocytes leads to a formation of a distinct pattern of pentamer PLB. Multiple PLB bands appear in addition to PLB<sub>5</sub> (the pentamer). This is accompanied by a reduced abundance of PLB<sub>5</sub> in comparison with the control.

The nature of the Western blot banding pattern is further evaluated by substituting PLB-deficient Sol8 cells in place of cardiac myocytes. Sol8 cells are infected with the recombinant adenovirus expressing either the transgene sPLB or K3E/R14E alone or in combination. As seen in Figure 6b, the Western blot shows that the monoclonal PLB antibody detects PLB in cells infected by sPLB but fails to detect K3E/R14E. Infection of Sol8 cells with a combination of the adenoviral transgenes results in formation of multiple bands of PLB. Moreover, the PLB pentamer decreases in abundance simultaneously with the appearance of the upper bands. It is well established that PLB interacts with and inhibits SERCA2a predominantly as a monomer that exists in equilibrium with the noninhibitory pentamer. Based on this knowledge, the heteropentamer of K3E/R14E and wild-type PLB might be more stable than the homopentamer of wild-type PLB. Therefore, the dissociation of the heteropentamer into monomers, which results in inhibition of SERCA2a, is disfavored. K3E/R14E interacts with endogenous PLB and forms such a complex, accompanied by a decrease in homopentamer formation. In as much, the monomer K3E/R14E may act as a noninhibitory competitor for endogenous wild-type PLB by blocking SERCA2a-PLB interaction sites.



-19-

The effects of mutant and antisense PLB on SERCA2a is further evaluated by determination of the SR calcium uptake activity. The initial rate of  $\text{Ca}^{2+}$  uptake by the SR measured at varying  $\text{Ca}^{2+}$  concentrations reflects the activity of SERCA2a. As shown in Figure 7, neonatal rat myocytes infected with the recombinant adenovirus transgenes K3E/R14E and asPLB show a decrease in the concentration of  $\text{Ca}^{2+}$  needed by SERCA2a for the same activity compared with the non-transgene control, indicating a stimulation of SERCA2a activity. The  $\text{EC}_{50}$ s of  $\text{Ca}^{2+}$  concentration at which the uptake activity is half-maximal are, (in  $\mu\text{mol/L}$ ), 0.20  $\pm$  0.02 for the non-transgene control (SR-), 0.11  $\pm$  0.01 for K3E/R14E, and 0.13  $\pm$  0.01 for asPLB. The effects of K2E/R14E and asPLB on SERCA2a are also examined in adult rat myocytes. The adenoviral transgene K3E/R14E lowers the  $\text{EC}_{50}$  significantly (by 36%), whereas the change as a result of asPLB infection is not within statistical significance. This apparent discrepancy in the effects between neonatal and adult cardiac myocytes is possibly related to the different abundances of PLB in myocytes at different developmental stages. PLB is nearly twice as abundant in adult as in neonatal myocardium.

To further examine the effects of K3E/R14E and asPLB on SERCA2a, intracellular  $\text{Ca}^{2+}$  transients in neonatal myocytes are measured by use of the indo 1 fluorescence indicator. Indo 1 ratiometric data which is obtained from each of the experimental conditions is normalized to the respective maximum and minimum of each contractile  $\text{Ca}^{2+}$  transient and is then aligned and averaged. As shown in Figure 8, the decay curves of K3E/R14E and asPLB are displaced to the left of the LacZ control. Furthermore, for most of the diastolic time points, K3E/R14E is significantly different from LacZ, whereas at several diastolic time points, asPLB is also significantly different from LacZ. The half-times for decay ( $\text{RT}_{50}$ ) for LacZ, K3E/R14E, and asPLB are determined to be 0.28 seconds (100%), 0.20 seconds (73%), and 0.22 seconds (79%), respectively.

-20-

The values for K3E/R14E (73%) and asPLB (79%) are significantly different ( $p < 0.05$ ) from the values obtained from the LacZ expressing virus.

In addition to generating adenoviral transgenes using various point mutations of PLB, or the sense or antisense sequences of PLB, antibodies raised against PLB peptide and then expressed as RNA can also be inserted into the adenoviral vector. To raise polyclonal PLB antibody ("contractilin", or chicken antibody peptides with hyperactive regions), a chicken is repeatedly immunized with PLB peptide which represents amino acids 3 to 19 of the cytoplasmic domain. After three rounds of booster immunization, administered at 15, 42 and 54 days, total IgY is purified from the egg yolk, using a commercially available purification system (EGGstract IgY Purification System - Promega). Upon confirmation of a positive immune response, lymphocytes from the spleen and bone marrow are harvested. RNA, in the form of the hypervariable regions from both antibody light and heavy chain is obtained from these cells and amplified by RT-PCR, the method of which is well known.

The amplified and purified hypervariable region RNA is then fused to a single cDNA (Seq. ID. No. 9) and subsequently cloned in frame into a plasmid vector, coding for a phage surface protein. Using standard phage display technique, phages which express the immune library of the chicken are selected by their positive response to the PLB peptide. After a series of enrichment for phages which specifically bind PLB, 20 clones are selected for ELISA. The resulting 5 best binders are then analyzed using a radioactive  $\text{Ca}^{2+}$  transport assay. The two best activators of SR  $\text{Ca}^{2+}$  transport are further analyzed. Both clones are found to dramatically stimulate the rate of  $\text{Ca}^{2+}$  transport into the SR.

To demonstrate that the recombinant protein, which has been generated from contractilin (the PLB antibody), can also function inside a living cell, an adenoviral vector expressing contractilin is constructed.

-21-

Western blot analysis of neonatal and adult rat cardiomyocytes, infected with the adenoviral transgene, shows that contractilin can be expressed in heart cells. Radioactive  $\text{Ca}^{2+}$  transport analysis indicate that, as with the mutant and antisense PLB, contractilin accelerates cytoplasmic  $\text{Ca}^{2+}$  removal.

In a complementary approach, plasmid transfection rather than adenoviral transfection is used for gene delivery. It is found that K3E/R14E- and asPLB- transfected myocytes, as monitored by co-transfected green fluorescence protein, exhibits 43% ( $p < 0.05$ ) and 9% ( $p < 0.1$ ) decreases in  $\text{RT}_{50}$ , respectively, relative to adenoviral vector transfected cells. Thus, introducing K3E/R14E and asPLB into the cardiac myocytes by either the adenovirus or co-transfection technique reduces the duration of the diastolic  $\text{Ca}^{2+}$  transients. These results would seem to mirror the findings of MLPKO versus DKO mice where variation in  $\text{Ca}^{2+}$  transients confirm that ablation of PLB is associated with a shortened duration of  $\text{Ca}^{2+}$  transient, faster decay, and preserved amplitude. Taken together, these data confirm that K3E/R14E and asPLB stimulate the SERCA2a activity, which results in faster  $\text{Ca}^{2+}$  transients in myocytes.

To determine whether the enhanced SERCA2a activity and accelerated  $\text{Ca}^{2+}$  transients, as a result of the PLB mutants, lead to change in contractile behavior, edge detection is used to analyze myocyte contractility. Adult rabbit myocytes are infected with the adenoviral transgenes of LacZ, K3E/R14E, or asPLB. After a three day incubation period, there is a significant difference in the number of spontaneously contracting cells between the different groups ( $\text{LacZ} < \text{asPLB} < \text{K3E/R14E}$ ). Table 2 provides the effects of K3E/R14E and asPLB on myocyte contractility. As shown in the table, compared with the LacZ control, K3E/R14E increases fractional shortening by 74%, which is accompanied by a 25% decrease in  $\text{RT}_{50}$  and a 115% increase in  $+dL/dt$ . When the myocyte contractility is examined after asPLB infection, it is

-22-

found that the fractional shortening of the myocytes increases significantly, by 57%, whereas the changes in  $RT_{50}$  and  $+dL/dt$  are not significant.

Table 2

	LacZ (n = 33)	K3E/R14E (n = 29)	asPLB (n = 30)
+dL/dt ( $\mu\text{m/s}$ )	$11.7 \pm 1.9$	$25.1 \pm 1.6^*$	$18.4 \pm 2.0^*$
$RT_{50}$ (ms)	$539.0 \pm 27.0$	$402.0 \pm 19.0^*$	$483.0 \pm 29.0^{***}$
Shortening (%)	$6.2 \pm 0.5$	$10.8 \pm 0.5^*$	$8.0 \pm 0.6^{***}$

\*:  $p < 0.05$

\*\*:  $p < 0.1$

The resulting data show that the increase in SERCA2a activity translates into an accelerated relaxation of the myocytes. K3E/R14E-infected myocytes display an enhanced fractional shortening, which suggests an increase in SR loads of  $\text{Ca}^{2+}$  due to the enhancement of SERCA2a activity. Further, K3E/R14E infection increases the number of spontaneously contracting myocytes, a phenomenon most likely associated with the increased amount of oscillating  $\text{Ca}^{2+}$  due to the elevated SR loading of  $\text{Ca}^{2+}$ . Taken together, these data show that K3E/R14E affects endogenous wild-type PLB in a way that significantly reduces its inhibition of SERCA2a and thus has a dominant inhibitory effect over wild-type PLB.

#### *Peptide-based therapeutic for inhibition of PLB activity*

Still further, the present invention provides for a peptide based therapeutic for the inhibition of phospholamban activity and a mode of delivery for such a therapeutic, based on the finding that PLB function can be inhibited in a dominant negative manner by overwhelming endogenous PLB with mutant PLB molecules, and that this inhibition leads to improved function in failing hearts.

-23-

For a therapeutic agent, such as an inhibitor of the PLB-SERCA2a interaction, to effect a target cell system, it must have a means for internalization through the cell membrane into the cytoplasm. The mode of transfer of the inhibitor can be by way of either a transport or  
5 penetratin based PLB peptide or it can also include adenoviral or lipid vesicle based transfer. For this purpose, a compound consisting of a fusion of a transport peptide and a PLB protein molecule is constructed. The transport peptide comprises a 16-residue from the sequence for antennapedia, a Drosophila transcription factor protein. The second  
10 peptide of the complex can be a truncated sequence of PLB protein. Further therapeutic benefits can be achieved using peptides that correspond to native PLB protein as well as a mutant or truncated form of PLB protein.

One beneficial function of the transport peptide-PLB complex is the  
15 inhibition of the interaction between PLB and SERCA2a within cardiomyocytes, resulting in enhanced contractility in diseased hearts. The present invention may also inhibit the interaction of PLB with SERCA2a within the smooth muscle layer surrounding the arteries/  
arterioles of the circulatory system which would result in vasodilation and  
20 reduced blood pressure. Thus, there is a two-fold benefit in the treatment of heart disease, the first is enhanced cardiac contractility in failing hearts, the other is the reduction of blood pressure in individuals with hypertension. It is also predicted that there will be the inhibition of PLB interactions with SERCA proteins of other cell types, such as the  
25 SERCA1-PLB interaction in nervous tissue.

The introduction of the molecule into the blood stream feeding the heart can be best achieved using a catheter located in the coronary artery. When the molecule is present in the extracellular environment surrounding a cardiomyocyte it rapidly enters the cardiomyocyte and inhibits the  
30 association of PLB with SERCA2a. The translocation function is

-24-

attributable to the transport peptide which exhibits the ability to rapidly translocate itself and the attached "cargo" peptides across the cell membranes in a receptor independent manner. Once inside the cytoplasm of the cardiomyocyte, the PLB fragment will act as a competitive inhibitor of endogenous PLB interactions with SERCA2a.

In the absence of PLB inhibition by association, SERCA2a more efficiently pumps  $\text{Ca}^{2+}$  into the SR, thereby increasing the cardiomyocytes ability to contract more strongly and rapidly. Stronger cardiomyocyte contractility translates to more powerful heart contractility. *In vivo*, the present invention could act as a treatment for heart failure and is most easily administered and most effective in patients whose hearts require, or already have implanted, a left-ventricular assist device (LVAD).

While residues 43 to 58 of Antennapedia is a well characterized translocation peptide, and works well in the present invention, the present invention is not restricted to this method of transport. Other potential methods of transfer include the use of an 8-branched polylysine backbone to link the transport and cargo peptide, but it is not limited to this multi-branched structure. A compound consisting of one target peptide attached to one PLB peptide, as one long peptide, has also been explored. Still further, a number of DNA constructs for producing hexahistidine (H6) tagged penetratin and penetratin-PLB recombinant proteins in bacteria have been undertaken. The penetratin peptides were engineered to be on either the amino or carboxy terminal end of the protein.

It has been shown that the cytoplasmic fragment of PLB has as strong a binding affinity for the cytoplasmic portion of SERCA2a as the whole PLB molecule. Therefore, once the transport-PLB molecule is inside the cytoplasm of the cardiomyocyte, the PLB fragment is predicted to act as a competitive inhibitor of endogenous PLB interaction with SERCA2a.

This form of treatment is suitable for the patient who is suffering from severe decreased cardiac pump function, refractory to medical

-25-

therapy, and requiring mechanical assistant devices while waiting for heart transplantation. In addition, the underlined molecular mechanisms for the dominant negative function of the PLB mutants can be used in the design and implementation of the high-throughput screening strategies for inhibitory small molecules.

The following examples are intended to illustrate but not limit the present invention.

### EXAMPLE 1

#### 10 Creation of knock-out mouse lines for echocardiography

In order to analyze the structural and physiological features of the complex *in vivo* heart failure phenotype of dilated cardiomyopathy, several lines of knock-out mice were created. conducted using a double knock-out (DKO) mouse model which harbors homozygous ablation of two independent muscle specific genes. For this strategy, PLB<sup>-/-</sup> (phospholamban deficient) homozygous mice were mated with MLP<sup>-/-</sup> (muscle-specific LIM protein) homozygous mice. The F1 pups generated from an MLP<sup>-/-</sup> x PLB<sup>-/-</sup> homozygote cross were then mated to create the MLP<sup>+/-</sup>, PLB<sup>+/-</sup> double heterozygote genotype. F2 offspring were generated from a MLP<sup>+/-</sup> / PLB<sup>+/-</sup> double heterozygote mating, thereby creating mice that were homozygous for the mutant MLP allele and heterozygous for the mutant PLB allele or that were MLP wild-type and heterozygous for the mutant PLB allele. The F3 offspring were generated from a MLP<sup>-/-</sup> / PLB<sup>+/-</sup> matings to generate MLP<sup>-/-</sup> / PLB<sup>-/-</sup> (DKO), MLP<sup>-/-</sup> / PLB<sup>+/-</sup> (MLPKO) and MLP<sup>+/-</sup> / PLB<sup>-/-</sup> (MLPKO/ PLBhet) littermates or from a MLP<sup>+/-</sup> / PLB<sup>+/-</sup> matings to generate MLP<sup>+/-</sup> / PLB<sup>-/-</sup> (PLBKO), MLP<sup>+/-</sup> / PLB<sup>+/-</sup> (wild-type) and MLP<sup>+/-</sup> / PLB<sup>+/-</sup> (PLBhet) littermates. The genotype of the gene-targeted crosses were determined by PCR or genomic DNA isolated from tail biopsies.

30 To evaluate the hemodynamic properties of the various knock-out

-26-

mouse lines, cardiac catheterization and echocardiography was performed on subjects anesthetized with either Avertin (2.5%, 20  $\mu$ l/kg body weight) or xylazine (0.005 mg/g) and ketamine (0.1 mg/g). Transthoracic M-mode echocardiographic tracings indicated that MLPKO mice had chamber

5 dilation with reduced wall motion, indicating depressed cardiac function and increased wall stress, whereas chamber size and cardiac function are normal in the DKO mice. Baseline parameters for wild-type (WT), n = 7, MLPKO, n = 8, DKO, n = 9, and PLBKO, n = 5 are shown in Figures 2a-d. Data were expressed as mean  $\pm$  SEM. MLPKO versus other groups;

10 \*p < 0.5, \*\*p < 0.001, WT vs. DKO; #p < 0.01. In Figures 2e-h, hemodynamic assessment was made of  $\beta$ -adrenergic responsiveness to progressive infusion of dobutamine, where WT ( $\square$ ), n = 7, MLPKO ( $\bullet$ ), n = 8, and DKO ( $\circ$ ), n = 9, mice. MLPKO vs WT or DKO; #p < 0.05, +p < 0.01, \*p < 0.001, WT vs DKO;  $\exists$ p < 0.01.

15

## EXAMPLE 2

### Calcium transient analysis

To evaluate the effect of inhibition of PLB on SR calcium content and calcium transients, myocytes were isolated from the right ventricular

20 wall of the wild-type or knock-out mice. To monitor the changes in intracellular calcium, the isolated myocytes were incubated with a calcium sensitive dye, fluo-3-AM (1  $\mu$ g/ml), for 30 minutes at room temperature. The myocytes were then transferred to a tissue chamber on the stage of an inverted microscope and continuously stimulated at a rate of 1 Hz to

25 maintain a consistent degree of SR calcium loading. To measure cellular fluorescence, the myocytes were illuminated with an excitation wavelength of 480 nm. Any changes in fluorescence were monitored at 510 nm using a microfluorometer (FM-1000; Solam re Technologies) and digitally recorded for later analysis using Cellsoft (D. Bergman; University

30 of Calgary) software. Fluorescence values were calibrated using the



-27-

equation:

$$[Ca^{2+}]_i = K_D(F - F_{min}) / (F_{max} - F) \quad (1)$$

with an assumed  $K_D$  of 864 nM, where  $F$  are the experimentally derived fluorescence values.  $F_{max}$  was determined by adding 10  $\mu$ M ionomycin to the superfusion solution and  $F_{min}$  was determined by adding 4 mM  $MnCl_2$  to the superfusion solution for each myocyte.

SR calcium content of the isolated myocytes was assessed using a standard caffeine pulse protocol. Following stable recordings of calcium transients, a 20 second pulse of 10 mM caffeine was applied to the myocyte. This protocol resulted in a rapid caffeine-induced transient which slowly decayed back to baseline values. The SR calcium content was defined as the integrated area of this caffeine-induced calcium transient. Figure 3a illustrates the representative intracellular calcium transient in the WT, MLPKO and DKO myocytes. MLPKO myocytes exhibited an attenuated amplitude of calcium transients with normal levels of diastolic calcium concentration. DKO myocytes displayed the calcium transient with a shortened duration, faster decay, and preserved amplitude. As shown in Figure 3b, the amplitude of calcium transient was significantly attenuated in MLPKO myocytes and was restored in DKO myocytes. Figure 3c shows that intracellular diastolic calcium concentration was not different among the three different groups of myocytes. In Figure 3d, SR calcium content was significantly decreased in MLPKO mice and increased in DKO mice when compared to WT mice. In Figure 3e, representative quantitative immunoblotting revealed that MLP deficiency was not associated with any significant alterations in the protein levels of SERCA2a, PLB, and calsequestrin.

### EXAMPLE 3

#### Construction of mutant PLB adenovirus and gene transfer

I.M.A.G.E. consortium cDNA clones encoding human PLB were

-28-

available through Genome System, Inc. The DNA fragment harboring the entire coding sequence of PLB was subcloned into pBluescriptII KS vector, as well known *E. coli* cloning vector (ATCC accession no. 87047). A sense mutation (Val49Ala) was introduced using a PCR based

5 mutagenesis system commercially available from Stratagene.

Recombinant adenovirus expressing wild-type and mutant human PLB was generated by homologous recombination between plasmid pJM17 and a shuttle plasmid containing RSV promoter and SV40 poly A sequences.

10 The concentrated virus preparation were tittered using a standard protocol. The efficient *in vivo* cardiac gene transfer was performed by injecting the adenovirus vectors into 1 day old neonatal mouse heart. The myocytes were isolated 4 weeks after injection into the mouse hearts and cell shortening was measured. Myocytes harboring the mutant transgenes were identified by co-transfection of adenoviral vectors expressing GFP as  
15 a marker.

#### EXAMPLE 4

##### Construction of a PLB inhibitor-transport peptide complex

A PLB inhibitor molecule was made by indirectly attaching a  
20 transport peptide and a PLB protein to a polylysine backbone. Alternatively, the PLB molecule could also have been made as a single long peptide consisting of a transport sequence tandemly attached to the cargo peptide sequence. The transport peptide was composed of residues 43 to 58 of antennapedia (Seq. ID. No. 7), a *Drosophila* transcription  
25 factor protein. The cargo peptide was derived using the first 16 residues of PLB (Seq. ID. No. 8). It is important to note that this cargo sequence could also have been derived from any segment of wild-type PLB or mutant PLB.

The PLB inhibitor molecule was constructed by linking 4 transport  
30 peptides with 4 peptides matching the first 16 residues of PLB. The

-29-

backbone linker was an 8-branch lysine, commonly used in multiple antigenic peptide (MAP) synthesis. The first 4 branches of the MAP resin were used to synthesize the antennapedia peptide. The next 4 branches were then deprotected and used as the starting point for the synthesis of the PLB cargo peptide. Thus, this particular PLB inhibitor that was used for initial characterization had 4 branches of the antennapedia peptide and 4 branches of the PLB cargo peptide. Alternatively, the PLB inhibitor could have been constructed as a single peptide with the cargo and transport peptides attached to each other by a single peptide bond, or as the cargo and transport peptides attached to each other by a disulfide bond. The PLB inhibitor molecule was translocated efficiently into isolated neonatal rat cardiomyocytes and showed a resulting enhanced contractility of the cell, the results of which can be seen in Figures 5a and b. Myocytes that overexpressed the V49A PLB point mutation showed increased contractility, while myocytes which overexpressed the wild-type PLB exhibited decreased contractility when compared to non-infected myocytes.

## EXAMPLE 5

### Penetratin peptides TAT and ANT

Cell level studies were done to evaluate the ability of two penetratin-based peptides, two mutant PLB-penetratin peptides, and two multiple antigen peptides (MAP) to strengthen the contraction cycle of isolated mouse cardiomyocytes. The two penetratin-based peptides include PLB-ANT (Seq. ID. No. 10) and TAT-PLB (Seq. ID. No. 11) each of which have a 20 residue portion of the PLB sequence attached to either the 5' end of ANT (Seq. ID. No. 14) or the 3' end of TAT (Seq. ID. No. 15). The two mutant PLB peptides, mutant PLB-ANT (Seq. ID. No. 12) and TAT-mutant PLB (Seq. ID. No. 13), display a S16E mutation of the 20 residue PLB sequence. The multiple antigen peptides include MAP with 8 penetratin

-30-

(ANT) domains and MAP with 4 penetratin domains and 4 PLB domains .

Each of the penetratin-PLB peptides were evaluated to measure their ability to strengthen the contraction cycle of isolated mouse cardiomyocytes, the idea being that the penetratin-PLB peptide would act as a dominant negative inhibitor of the PLB-SERCA2a interaction. The results of the TAT-PLB peptide on the isolated cardiomyocytes is shown in Table 3. For this data, tests were repeated on several sets of cardiomyocytes to determine relative change in length through the contraction cycle with the TAT-PLB peptide (samples 1-7) and without the peptide (controls 1-8). Each of the samples had an added concentration of 10  $\mu$ M of the TAT-PLB peptide while the controls had no added peptide.

Table 3

		Maximum Contract.	Minimum Contract.	% Contract.	$\Delta$ Length/ msec.	r <sup>2</sup> (fit)	Contract. Slope	Relax. Slope
15	control 1	100.63	92.978	7.604	-34.503	0.9696	29.935	0.9955
	control 2	91.146	83.301	8.607	-38.76	0.9943	28.736	0.9349
	control 3	115.45	100.05	13.339	-82.875	0.9768	89.054	0.9894
	control 4	105.00	102.04	2.819	-19.196	0.9842	10.497	0.9944
	control 5	83.747	79.637	4.908	-21.695	0.9971	12.184	0.9742
20	control 6	145.96	136.85	6.241	-50.185	0.9721	27.566	0.9912
	control 7	154.56	142.16	8.023	-76.607	0.9933	73.70	0.9928
	control 8	115.59	102.68	11.169	-59.643	0.9765	63.304	0.9789
	<b>Mean</b>	<b>114.010</b>	<b>104.962</b>	<b>7.839</b>	<b>-47.933</b>	<b>0.9830</b>	<b>41.872</b>	<b>0.9814</b>
	sample 1	112.57	101.17	10.127	-65.554	0.9865	59.875	0.9925
25	sample2	109.68	102.00	7.002	-30.267	0.9609	37.157	0.9790
	sample3	133.82	116.32	13.077	-79.242	0.9964	134.46	0.9878
	sample 4	81.61	67.871	16.835	-58.093	0.9961	65.017	0.9697
	sample 5	74.423	64.629	13.160	-54.353	0.9539	47.775	0.9933
	sample 6	126.89	108.38	14.587	-98.054	0.9819	107.07	0.9939
30	sample 7	133.61	128.21	4.042	-36.071	0.9966	27.911	0.9959
	<b>Mean</b>	<b>110.373</b>	<b>98.363</b>	<b>11.261</b>	<b>-60.233</b>	<b>0.9818</b>	<b>68.466</b>	<b>0.9874</b>

-31-

Measurements were taken every 20 milliseconds, and the unit of length was arbitrary, but was generally on the order of one complete cell length. Percent contraction was calculated as (maximum length minus minimum length) divided by maximum length. A plot of time versus length  
5 generated a U-shaped curve from which the most linear segments were selected, with the left side of the "U" representing contraction and the right side representing relaxation. The  $r^2$  column shows how well the data fit the curve, where 1.0 represents a perfect fit.

While there appeared to be a trend towards a larger, faster  
10 contraction in the myocyte, T-test analysis not identify any statistical difference due to the high variability of the data.

### EXAMPLE 6

#### Hexahistidine tagged penetratin

15 A number of DNA constructs were generated for producing hexahistidine (H6) tagged penetratin and penetratin-PLB recombinant proteins in bacteria. Using a commercially available expression vector, pRSET (Invitrogen), recombinant protein H6-ANT (Seq. ID. No16) was generated. While this recombinant protein has no PLB attached, it was  
20 engineered to have epitope tags which was used to detect the protein as it entered the heart. A variation of H6-ANT was also expresses containing the PLB sequence, H6-wtPLB-ANT (Seq. ID. No. 17), in addition to an H6-PLB(S16E mutant)-ANT protein and an H6-PLB (V49A mutant)-ANT protein (Seq. ID. Nos. 18 and 19 respectively). H6-beta-galactosidase-  
25 ANT, H6-TAT, and H6-beta-galactosidase-TAT were also expressed at lower levels (seq. not listed). A non-functional ANT-penetratin with two mutations at residues 68 and 67, where Trp was mutated to Phe were made as negative control for the other three penetratin-PLB proteins.

To measure the effect these recombinant penetratin-based proteins  
30 have on cardiac contraction, one mouse was injected intraperitoneally

-32-

with 2 mg of the H6-ANT peptide. A second mouse was injected intraperitoneally with 2 mg of the H6-ANT mutant protein. After a 3 hour incubation period, the mice were sacrificed and the hearts removed for analysis. The blood in the heart was removed by forcing fluid backwards through the aortic arch. Each heart was dissected into atrial tissue, left ventricular tissue, and right ventricular tissue. All the tissue was washed extensively in a physiologically balanced PBS solution and flash frozen in liquid nitrogen. The tissue were then lysed in 8 M Urea, 2% triton-X100, for 10 minutes and equal amounts of the supernatants were electrophoresed on 15% PAGE. The bands were transferred to a PVDF membrane. The membranes were labeled with anti-His antibody in order to identify if the lysate contained the epitope tagged protein.

The invention disclosed herein provides several methods for the treatment of heart failure through the inhibition or alteration of the interaction between phospholamban and sarcoplasmic reticulum  $\text{Ca}^{2+}$  - ATPase within the cardiomyocytes. Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

-33-

What is claimed is:

1. A method for treatment of heart failure comprising inducing phospholamban deficiency.

2. The method for treatment of heart failure of claim 1, wherein  
5 an exogenous phospholamban protein induces phospholamban deficiency.

3. The method for treatment of heart failure of claim 2, wherein the exogenous phospholamban protein is selected from the group consisting of mutations of PLB, sense PLB, antisense PLB, truncated PLB, native PLB, and antibody against PLB.

10 4. The method for treatment of heart failure of claim 3, wherein the mutations of PLB comprise point mutations of PLB.

5. The method for treatment of heart failure of claim 3, wherein the antibody against PLB comprises contractilin.

6. A peptide based therapeutic agent for inhibiting  
15 phospholamban activity consisting of a first peptide and a second peptide as a complex, wherein the first peptide comprises a transport peptide and the second peptide comprises a cargo peptide.

7. The peptide based therapeutic agent of claim 6, wherein the transport peptide is selected from the group consisting of penetratin,  
20 adenovirus, bacterial and lipid vesicle based transport peptide.

8. The peptide based therapeutic agent of claim 6, wherein the cargo peptide is selected from the group consisting of mutations of PLB, sense PLB, antisense PLB, truncated PLB, and native PLB protein.

9. The peptide based therapeutic of claim 6, wherein the first  
25 peptide transports the second peptide across a cell membrane.

10. The peptide based therapeutic of claim 6, wherein the first peptide and the second peptide are linked by a covalent linkage.

11. The peptide based therapeutic of claim 10, wherein the covalent linkage consists of a branched polylysine backbone, a single  
30 peptide bond, or a disulfide bond.

-34-

12. A method for treatment of heart failure comprising enhancement of cardiac contractility by inhibition of PLB-SERCA2a interaction.

5 13. The method of claim 12, wherein the cardiac contractility is enhanced by inhibiting effect of PLB on sarcoplasmic reticulum  $\text{Ca}^{2+}$  ATPase.

14. The method of claim 12, wherein an exogenous phospholamban protein is used to inhibit phospholamban deficiency.

10 15. The method of claim 14, wherein the exogenous phospholamban protein is selected from the group consisting of mutations of PLB, sense PLB, antisense PLB, truncated PLB, native PLB, and antibody against PLB.

16. The method of claim 15, wherein the mutations of PLB comprise point mutations of PLB.

15 17. The method for treatment of heart failure of claim 15, wherein the antibody against PLB comprises contractilin.



1/9




FIG. 1

2/9




FIG. 2a




FIG. 2b




FIG. 2c




FIG. 2d

3/9




FIG. 2e




FIG. 2f




FIG. 2g




FIG. 2h

4/9




FIG. 3a

5/9




FIG. 3b




FIG. 3c




FIG. 3d




FIG. 4b

6/9




FIG. 3e




FIG. 4a




FIG. 5a

	CONTROL n = 7	WILDTYPE PLB n = 3	V49A MUTANT PLB n = 4
SHORTENING %	7.20	3.50	11.45
-dL/dt (mm)	88.4	48.4	150.3
+dL/dt (mm)	56.6	28.1	116.5
CELL LENGTH(μm)	104.5	109.2	108.7

FIG. 5b

8 / 9




FIG. 6a




FIG. 6b



FIG. 6c



9/9




FIG. 7




FIG. 8

## SEQUENCE LISTING

<110> Kenneth Chien, Wolfgang Dillman, Susumu Minamisawa,  
 Huaping He, Masahiko Hoshijima, Markus Meyer, Christopher  
 Scott, Yibin Wang, Gregg Silverman

<120> A METHOD FOR INHIBITION OF PHOSPHOLAMBAN  
 ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE  
 AND HEART FAILURE

<130> 6627-9025

<140> unknown

<141> November 2, 1999

<150> US 60/106,718

<151> November 2, 1998

<160> 9

<170> Word Perfect 8.1

<210> 1

<211> 52

<212> PRT

<213> Human Phospholamban

<220> wild type

<221> amino acid sequence

<222> 1...52

<400> 1

Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser Thr Ile  
 1 5 10 15

Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe  
 20 25 30 35

Cys Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu 52  
 40 45 50

<210> 2

<211> 52

<212> PRT

<213> Human Phospholamban

<220> Val49Ala mutant

<221> amino acid sequence

<222> 1...52

&lt;400&gt; 2

Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser Thr Ile  
 1 5 10 15

Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys  
 20 25 30 35

Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Ala Met Leu Leu 52  
 40 45 50

&lt;210&gt; 3

&lt;211&gt; 52

&lt;212&gt; PRT

&lt;213&gt; Human Phospholamban

&lt;220&gt; Glu2Ala mutant

&lt;221&gt; amino acid sequence

&lt;222&gt; 1...52

&lt;400&gt; 3

Met Ala Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser Thr Ile  
 1 5 10 15

Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys  
 20 25 30 35

Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu 52  
 40 45 50

&lt;210&gt; 4

&lt;211&gt; 52

&lt;212&gt; PRT

&lt;213&gt; Human Phospholamban

&lt;220&gt; Arg14Glu mutant

&lt;221&gt; amino acid sequence

&lt;222&gt; 1...52

&lt;400&gt; 4

Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Glu Ala Ser Thr Ile  
 1 5 10 15

Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys  
 20 25 30 35

Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu 52  
 40 45 50

<210> 5  
 <211> 52  
 <212> PRT  
 <213> Human Phospholamban

<220> Ser16Asn mutant  
 <221> amino acid sequence  
 <222> 1...52

<400> 5  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Asn Thr Ile  
 1 5 10 15

Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys  
 20 25 30 35

Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu 52  
 40 45 50

<210> 6  
 <211> 52  
 <212> PRT  
 <213> Human Phospholamban

<220> Lys3Glu/Arg15Glu mutant  
 <221> amino acid sequence  
 <222> 1...52

<400> 6  
 Met Glu Glu Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Glu Ala Ser Thr Ile  
 1 5 10 15

Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn Leu Phe Ile Asn Phe Cys  
 20 25 30 35

Leu Ile Leu Ile Cys Leu Leu Leu Ile Cys Ile Ile Val Met Leu Leu 52  
 40 45 50

<210> 7  
 <211> 16  
 <212> PRT  
 <213> Drosophila

<220> antenpedia  
 <221> amino acid sequence  
 <222> 1...16

<400> 7  
 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
 1 5 10 15

<210> 8  
 <211> 16  
 <212> PRT  
 <213> Human Phospholamban

<220> carboxy terminal  
 <221> amino acid sequence  
 <222> 1...16

<400> 8  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser  
 1 5 10 15

<210> 9  
 <211> 269  
 <212> PRT  
 <213> Contractilin

<220>  
 <221> amino acid sequence  
 <222> 1...269

<400> 9

Met His His His His His Val Ala Gln Ala Ala Leu Thr His Ser Ser Ser  
 1 5 10 15

Val Ser Ala Asn Pro Gly Glu Thr Val Lys Ile Thr Cys Ser Gly Gly Gly Asn  
 20 25 30 35

Tyr Ala Gly Ser Tyr Tyr Tyr Gly Trp Phe Gln Gln Lys Ser Pro Gly Ser Ala

40	45	50
Pro Val Thr Val Ile Tyr Ser Asn Asp Gln Arg Pro Ser Asn Ile Pro Ser Arg		
55	60	65 70
Phe Ser Gly Ser Thr Ser Gly Ser Thr Ser Thr Leu Thr Ile Thr Gly Val Arg		
75	80	85 90
Ala Glu Asp Glu Ala Val Tyr Phe Cys Gly Ser Asn Ser Gly Thr Gly Tyr Val		
95	100	105
Gly Ile Phe Gly Ala Gly Thr Thr Leu Thr Val Leu Gly Gln Ser Ser Arg Ser		
110	115	120 125
Ser Thr Val Thr Leu Asp Glu Ser Gly Gly Gly Leu Gln Thr Pro Gly Gly Ala		
130	135	140
Leu Ser Leu Val Cys Arg Ala Ser Gly Phe Thr Phe Ser Arg Phe His Met		
145	150	155 160
Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Gly Ile Asp		
165	170	175
Asp Gly Gly Ser Phe Thr Leu Tyr Gly Ala Ala Val Lys Gly Arg Ala Thr Ile		
180	185	190 195
Leu Arg Asp Asn Gly Gln Ser Thr Val Arg Leu Gln Leu Asp Asn Leu Arg		
200	205	210
Pro Glu Asp Thr Ala Thr Tyr Phe Cys Val Lys Thr Lys Cys Gly Gly Asn		
215	220	225 230
Gly Trp Cys Gly Ala Asp Arg Ile Asp Ala Trp Gly His Gly Thr Glu Val Ile		
235	240	245
Val Ser Ser Thr Ser Gly Gln Ala Gly Gln Tyr Pro Tyr Asp Val Pro Asp Tyr		
250	255	260 265
Ala Ser		
269		

<210> 10  
 <211> 36  
 <212> PRT  
 <213> Human Phospholamban

<220> PLB-ANT  
 <221> amino acid sequence  
 <222> 1...36

<400> 10  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser Thr Ile  
 1 5 10 15

Glu Met Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
 20 25 30 35

<210> 11  
 <211> 35  
 <212> PRT  
 <213> Human Phospholamban

<220> TAT-PLB  
 <221> amino acid sequence  
 <222> 1...35

<400> 11

Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Met Glu  
 1 5 10 15

Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Ser Thr Ile Glu Met  
 20 25 30 35

<210> 12  
 <211> 36  
 <212> PRT  
 <213> Human Phospholamban

<220> Ser16Glu PLB mutant-ANT  
 <221> amino acid sequence  
 <222> 1...36

<400> 12

Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Glu Thr Ile  
 1 5 10 15

Glu Met Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
 20 25 30 35

<210> 13  
 <211> 35  
 <212> PRT  
 <213> Human Phospholamban

<220> TAT- Ser31Glu PLB mutant  
 <221> amino acid sequence  
 <222> 1...35

<400> 13  
 Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Met Glu  
 1 5 10 15

Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala Glu Thr Ile Glu Met  
 20 25 30

<210> 14  
 <211> 16  
 <212> PRT  
 <213> Drosophila

<220> ANT  
 <221> amino acid sequence  
 <222> 1...16

<400> 14  
 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
 1 5 10 15

<210> 15  
 <211> 11  
 <212> PRT  
 <213> HIV

<220> TAT  
 <221> amino acid sequence  
 <222> 1...11



<400> 15  
 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
 1 5 10

<210> 16  
 <211> 61  
 <212> PRT  
 <213> E. coli

<220> H6-ANT  
 <221> amino acid sequence  
 <222> 1...61

<400> 16  
 Met Arg Gly Ser His His His His His His Gly Met Ala Ser Met  
 1 5 10 15

Thr Gly Gly Gln Gln Met Gly Arg Asp Leu Tyr Asp Asp Asp Asp  
 20 25 30

Lys Asp Pro Ser Ser Arg Ser Ala Ala Gly Thr Met Glu Phe Arg  
 35 40 45

Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys  
 50 55 60

Ala  
 61

<210> 17  
 <211> 79  
 <212> PRT  
 <213> E. coli

<220> H6-wtPLB-ANT  
 <221> amino acid sequence  
 <222> 1...79

<400> 17  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala  
 1 5 10 15

Ser Thr Ile Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn  
 20 25 30

Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu Ile  
                   35                  40                  45

Cys Ile Ile Val Met Leu Leu His His His His His His Lys Gly  
                   50                  55                  60

Glu Phe Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys  
                   65                  70                  75

Trp Lys Lys Ala  
                   79

<210> 18  
 <211> 79  
 <212> PRT  
 <213> E. coli

<220> H6-PLB (Ser16Glu mutant)-ANT  
 <221> amino acid sequence  
 <222> 1...79

<400> 18  
 Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala  
 1                  5                  10                  15

Glu Thr Ile Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn  
                   20                  25                  30

Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu Ile  
                   35                  40                  45

Cys Ile Ile Val Met Leu Leu His His His His His His Lys Gly  
                   50                  55                  60

Glu Phe Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys  
                   65                  70                  75

Trp Lys Lys Ala  
                   79

<210> 19

<211> 79  
<212> PRT  
<213> E. coli

<220> H6-PLB (Val49Ala mutant)-ANT  
<221> amino acid sequence  
<222> 1...79

<400> 19  
Met Glu Lys Val Gln Tyr Leu Thr Arg Ser Ala Ile Arg Arg Ala  
1 5 10 15

Ser Thr Ile Glu Met Pro Gln Gln Ala Arg Gln Lys Leu Gln Asn  
20 25 30

Leu Phe Ile Asn Phe Cys Leu Ile Leu Ile Cys Leu Leu Leu Ile  
35 40 45

Cys Ile Ile Ala Met Leu Leu His His His His His Lys Gly  
50 55 60

Glu Phe Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys  
65 70 75

Trp Lys Lys Ala  
79

# INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 99/25692

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/17 A61K47/48 C07K17/00 A61P9/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KOSS K L ET AL: "PHOSPHOLAMBAN: A PROMINENT REGULATOR OF MYOCARDIAL CONTRACTILITY" CIRCULATION RESEARCH, vol. 79, no. 6, 1 December 1996 (1996-12-01), pages 1059-1063, XP002053754 ISSN: 0009-7330 the whole document	1-5, 12-17
X	DILLMANN W H: "Influences of increased expression of the Ca <sup>2+</sup> ATPase of the sarcoplasmic reticulum by a transgenic approach on cardiac contractility." ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1998 SEP 16) 853 43-8. , XP000914521 page 46, line 47 -page 47, line 16	1-5, 12-17
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 June 2000

Date of mailing of the international search report

20/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Stein, A

## INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 99/25692

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HE HUAPING ET AL: "Influence of an antisense phospholamban transcribed by an adenoviral vector on Ca-2+ ATPase in cardiac myocytes." JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 29, no. 6, 1997, page A181 XP000907558 ISSN: 0022-2828 the whole document ---	1-5, 12-17
X	WO 97 37224 A (MEDICAL RES COUNCIL ;BARFORD DAVID (GB); COHEN PHILIP (GB); COHEN) 9 October 1997 (1997-10-09) page 32, line 1 - line 7 ---	1,12,13
X	FR 2 753 722 A (SMITHKLINE BEECHAM LAB) 27 March 1998 (1998-03-27) the whole document ---	1,12,13
A	TOYOFUKU T ET AL: "Amino acids Glu2 to Ile18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca2+-ATPase of sarcoplasmic reticulum" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 4, 28 January 1994 (1994-01-28), pages 3088-3094, XP002139384 cited in the application the whole document ---	1-5, 12-17
A	US 5 652 122 A (PABO CARL ET AL) 29 July 1997 (1997-07-29) the whole document ---	6-11
P,X	MINAMISAWA SUSUMU ET AL: "Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy." CELL , vol. 99, no. 3, 29 October 1999 (1999-10-29), pages 313-322, XP002139385 ISSN: 0092-8674 the whole document ---	1-5, 12-17
	--- -/--	

# INTERNATIONAL SEARCH REPORT

Int. .tional Application No

PCT/US 99/25692

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>HE HUAPING ET AL: "Effects of mutant and antisense RNA of phospholamban on SR Ca<sup>2+</sup>-ATPase activity and cardiac myocyte contractility."</p> <p>CIRCULATION , vol. 100, no. 9, 31 August 1999 (1999-08-31), pages 974-980, XP000907563 ISSN: 0009-7322 the whole document</p> <p style="text-align: center;">----</p>	1-17
P,X	<p>WO 99 30696 A (HAIKALA HEIMO ;OVASKA MARTTI (FI); KAHEINEN PETRI (FI); KAIVOLA JU) 24 June 1999 (1999-06-24) the whole document</p> <p style="text-align: center;">-----</p>	1,12,13

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/25692

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9737224	A	09-10-1997	AU 2172597 A CA 2250826 A EP 0891551 A	22-10-1997 09-10-1997 20-01-1999
FR 2753722	A	27-03-1998	WO 9813518 A	02-04-1998
US 5652122	A	29-07-1997	US 5674980 A US 5804604 A US 5670617 A US 5747641 A AT 142266 T AU 658818 B AU 7182991 A CA 2071214 A DE 69028412 D DE 69028412 T DK 506884 T EP 0506884 A ES 2091916 T GR 3021474 T WO 9109958 A AT 173016 T AU 667244 B AU 5083293 A CA 2135642 A DE 69321962 D DE 69321962 T DE 656950 T EP 0656950 A EP 0903408 A ES 2123062 T FI 945248 A JP 2869396 B JP 10033186 A JP 2702285 B JP 7503617 T KR 153027 B NO 944273 A NZ 255831 A WO 9404686 A	07-10-1997 08-09-1998 23-09-1997 05-05-1998 15-09-1996 04-05-1995 24-07-1991 22-06-1991 10-10-1996 27-03-1997 04-11-1996 07-10-1992 16-11-1996 31-01-1997 11-07-1991 15-11-1998 14-03-1996 15-03-1994 03-03-1994 10-12-1998 01-07-1999 14-03-1996 14-06-1995 24-03-1999 01-01-1999 05-01-1995 10-03-1999 10-02-1998 21-01-1998 20-04-1995 15-10-1998 17-02-1995 24-04-1997 03-03-1994
WO 9930696	A	24-06-1999	AU 1565599 A US 5968959 A	05-07-1999 19-10-1999